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ABSTRACT
The malarial merozoite invades the erythrocyte and develops within the host cell. One of 
the most important and well studied parasite surface proteins at this stage of the life cycle 
is merozoite surface protein-1 (MSP-1). Plasmodium falciparum MSP-1 undergoes 
proteolytic processing into several fragments, of which only the carboxyl-terminal 19 kDa 
fragment (MSP-119) remains on the merozoite surface during invasion of a new 
erythrocyte. To study the importance of antibodies to the 19 kDa fragment of Plasmodium 
yoelii MSP-1 in providing protective immunity against infection, MSP-1-specific 
monoclonal antibodies were produced and characterised. Six antibodies were studied in 
detail. When naïve mice were passively immunised with these antibodies and then 
challenged with P. yoelii YM; which is a virulent and lethal parasite line, four of the 
antibodies showed a protective effect, reducing the level of parasitacmia and increasing 
host survival. There was some correlation between antibody subclass and protection.
The epitopes for the antibodies were located on MSP-1, two antibodies bound to a 
recombinant protein comprised of the whole of MSP-119, and two others bound to a 
smaller sub-domain of it. These antibodies also recognised a similar recombinant protein 
from P. yoelii 265 BY ; this cross-reaction occurred despite quite extensive sequence 
differences between the two polypeptides. Two other MSP-1 specific antibodies did not 
recognise recombinant MSP-119, one bound to an epitope in the protein sequence adjacent 
to MSP-119 and the second recognised a laiger structure tliat included MSP-119. Tliis panel 
of biologically active antibodies enables the mechanisms of antibody inhibition of 
erythrocyte invasion to be studied in detail.
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CHAPTER 1: INTRODUCTION
1.1 Malaria and the health problem
Malaria remains one of the most important priorities for improving public health in the 
tropical and subtropical areas of the world. The World Health Organisation estimates 
that there are 300 to 500 million clinical cases and approximately 2 to 3 million deaths 
due to malaria per year. The development of a vaccine against malaria is urgently 
needed in countries where the disease is endemic. In these regions there are serious 
problems in the control and eradication of malaria due to the increasing prevalence of 
insecticide-resistant mosquitoes, drugs-resistant parasites, and logistical problems in anti­
malaria campaigns (Cohen, 1994; Desowitz, 1996; Maurice & O’Brien, 1997). The need 
for a vaccine was emphasised by the committee set up by the Institute of Medicine, 
USA in 1984. A malaria vaccine topped the list of desperately needed vaccines (Cohen, 
1994).
Malaria is caused by protozoan parasites of the genus Plasmodium that belongs to the 
phylum Apicomplexa; protozoa that are characterised by the presence of an apical 
organelle complex at some stages in the life cycle. This apical complex consists of 
rhoptries and micronemes, secretory organelles that allow the invasion of host cells and 
tissues (Holder, 1994; Doury et al. 1993). There are four species of Plasmodium that 
infect humans and three of them, P. vivax, P. ovale and P. malariae, may cause severe 
illness. However, the species which causes the most serious illness and sometimes death 
is P. falciparum (Pf). The malaria parasite is a complex organism that is carried by 
Anopheline mosquitoes and enters the bloodstream of the vertebrate host when the
mosquito takes a blood meal. In man (a vertebrate host) the parasite grows through 
many stages, eventually bursting open red blood cells and causing a disease typified by 
fever and other symptoms. One of the major causes of pathology and mortality is the 
adherence of parasitised erythrocytes to the endothelium of cerebral and other capillaries, 
which can lead to vascular obstruction, frequently followed by coma and death. The 
principal objective of vaccines against blood stage parasites is the prevention or 
reduction of malaria and death in developing tropical countries, especially in Africa.
Chemotherapy is the main means of control of malaria in infected individuals, but there is 
a growing global problem of parasite multi-drug resistance. For example, mefloquine 
resistance was reported even before the drug had been routinely used, and halofantrine 
resistance has emerged concomitantly. Quinine and chloroquine have been used for 
longer periods, but in many places of world, chloroquine is no longer an effective 
treatment for falciparum malaria, and P. vivax has developed resistance in some parts of 
Oceania. Quinine has been used for more than 350 years, and a logical question is: 
“What is so special about quinine?”. There are several possible explanations. First, 
quinine’s intraparasitic target might be so specific that mutations which confer resistance 
can occur only at an exceptionally slow rate. It is also possible that modem strains of 
malaria parasites might be more resistant to quinine when compared to the strains of 
parasite that existed 300 years ago, so fiiat qumine resistance has developed slowly over 
centuries of use and an increase in the required dose has gone unnoticed. On the other 
hand, perhaps quinine had not been used frequently enough to exert a selective pressure 
uiitil recently (Meshnick, 1997).
Combination chemotherapy is a rational approach to tackle drug resistance in malaria. If 
drug combinations are used, these should have compatible pharmacokinetics and 
pharmacodynamics, no adverse pharmacological interaction and no additional toxicity. 
Pyrimethamine plus long acting sulphonamide (S/P) has been used very successfully, but 
it is no longer effective in areas of South-east Asia and its efficacy is fading in West 
Africa. Quinine is most often combined with tetracycline, doxycycline or S/P for the 
treatment of uncomplicated malaria, but the long treatment course required makes it 
impractical in most settings. A three-day combination of quinine and clindamycin has 
proved effective in semi-immune subjects in Brazil and Cameroon, but its efficacy in 
non-immune subjects has not been evaluated. (White & Olliaro, 1996).
1.2 Life cycle of the malaria parasite Plasmodium spp.
The life-cycle of the malaria parasite within the human host is complex (Figure 1.1). This 
cycle is initiated by the inoculation of sporozoites by the Anopheles mosquito. When the 
mosquito bites, it injects sporozoites and they move quickly through the bloodstream to 
the liver. The sporozoite invades an hepatocyte and then the parasite undergoes asexual 
multiplication, eventually forming merozoites (the hepatic schizogony phase). Finally the 
liver cells burst, releasing merozoites into the blood stream. In a few seconds, these 
merozoites invade red blood cells and within these cells the parasite undergoes further 
nuclear division. After intracellular multiplication within the red blood cell (the 
erythrocytic schizogony phase), the host cell is burst open, releasing more infectious 
merozoites, which rapidly reinvade fresh red blood cells to repeat the asexual 
erythrocytic cycle. Some parasites within infected red blood cells develop into 
gametocytes to initiate the parasite’s sexual stage. When the mosquito bites an infected
human, it may suck up gametocytes, which produce male and female gametes in the 
mosquito’s stomach. Each gamete is haploid and after fertilisation, the diploid zygote 
matures over the next few hours into a mobile ookinete. Eventually the ookinete reaches 
the stomach wall, passes between the epithelial cells to reach the basement membrane 
and forms an oocyst. Within the oocyst multiplication occurs and eventually it releases 
thousands of sporozoites (sporogony phase). These sporozoites migrate to the 
mosquito’s salivary glands to initiate the cycle of infection again (Cherfas, 1990; Knell, 
1991).
13 Rodent models of malaria infection
The unlimited supply of mice, and the availability of some species of rodent malaria 
parasites, have been invaluable in research towards development of malaria vaccines. 
These models have been very useful to identify and characterise different antigenic 
proteins that may be common to aU malaria parasites. For example, it was first shown 
that mice vaccinated with merozoite surface protein-1 (MSP-1, see below) of P. yoelii 
were protected against a parasite challenge with lethal P. yoelii YM (Holder & 
Freeman, 1981). This was extended to show that vaccination with a recombinant protein 
consisting of the C-terminal part of P. yoelii MSP-1 induced protective immunity in mice 
(Daly & Long, 1993; Ling et al„ 1994). The study of murine models can give vduable 
information relevant to the study of human parasites such as P. falciparum.
The pathology of rodent malaria is perhaps more difficult to define with the same clarity 
as is the pathology of the human disease. Li P. berghei infected mice (without cerebral 
malaria), uncontrolled parasitaemia may simply exhaust the ability of the host to generate
new blood cells, and the mice die as a result of anaemia. Other features of pathology in 
rodent malaria infections that may parallel those in humans, such as anaemia and 
hypoglycaemia, can be measured. In these situations, high tumour necrosis factor (TNF) 
concentrations in plasma are often observed, but not aU the clinical signs observed can be 
attributed to an increase in TNF concentration alone. Other factors such as the strain of 
mouse, the species or strain of parasite and the effective parasite dose have great 
influence (Butcher, 1996).
In order to have an insight into protective immunity in vivo, various murine models have 
been studied, using parasites isolated from wild rodents. These offer some advantages 
over simian malaria models because they can be easily handled, and are relatively cheap 
to maintain. In addition, the mouse immune system is well characterised and large-scale 
infection and vaccination studies may be performed and readily repeated if necessary. 
Some rodent parasite species such as P. berghei and P. vinkei, and some strains of P. 
yoelii and P. chabaudi cause lethal infection in mice. Others, including P. yoelii, P. 
chabaudi adami, P. chabaudi chabaudi and P. vinckei petteri, can cause limited 
infections in most laboratory strains of mice. There is an initial parasitaemia followed by 
either complete elimination of parasites (e.g. P. yoelii), or smaller patent recrudescent 
populations that can persist for several months (e.g. P. c. chabaudi and P. vinckei 
petteri) (Taylor-Robinson, 1995). The lethal infection models are often used to screen 
compounds for chemotherapeutic activity, and the non-lethal infections serve as models 
to investigate the mechanisms of acquired immunity.
It must be considered that although rodent malaria models are quite good systems for 
studying the immune response, laboratory mice are not the natural hosts of malaria
parasites. Therefore the information derived from analysis of murine infection models 
must be extrapolated with care to understand human malaria. For example in reference 
to the interpretation of parasitaemia, for most species of murine malaria acute 
parasitaemias peak at >30%, a level that far exceeds that of P. falciparum in humans, 
which only exceptionally rises above 10% (Taylor-Robinson, 1995). Despite this, the 
murine models offer numerous advantages for the study of malaria and should continue 
to provide information which currently can not be obtained from other models for either 
ethical or technical reasons.
1.3.1 Plasmodium yoelii
Rodent malaria parasite are classified into three groups, berghei, vinckei and chabaudi. 
The blood stages of the berghei group are morphologically indistinguishable and are 
notable for their marked predilection for immature erythrocytes in the blood of 
experimentally infected laboratory rodents. Parasites of this group (P. berghei and P. 
yoelii ssp.) are clearly distinguished by this characteristic from P. vinckei and P. 
chabaudi, neither of which has a preference for immature erythrocytes. The subspecies 
of P. yoelii are distinguishable by morphological characteristics of other stages, their 
geographical distribution and differences in isoenzyme patterns (Killick-Kendrick, 1974).
Plasmodium yoelii was isolated from a thicket rat (Thamnomys rutilans), trapped in the 
Central African Republic (Landau and Chabaud, 1965). The original isolate from a wild 
rat was adapted for growth in laboratory mice, producing a mild and chronic infectioiL 
When mice were inoculated with 10^  parasites, most were capable of spontaneously 
resolving the infection. By the fourth day the parasitaemia had risen to a level of 2-5%
and all available reticulocytes were parasitised; only 5% of the mice developed 
increasing parasitaemia, and died within two weeks, (Wery, 1966; Yoeli et al., 1975). 
When the 17X strain of P. berghei yoelii was inoculated into sixteen mice, only one of 
them developed high parasitaemia and died. However, following 110 days storage in a 
deep-freeze, a line of this strain immediately exhibited enhanced virulence causing high 
parasitaemia and the death of all infected mice. This virulence did not alter after eight 
blood passages or following cyclic transmission through Anopheles stephensi. This was 
the origin of the line that was renamed YM (or 17XL [L = lethal]) (Yoeli et al., 1975). It 
is well known that prolonged and continuous syringe passage of rodent malaria parasites 
under laboratory conditions can increase their virulence, perhaps by increasing their 
adaptation to a particular host, but the genetic relationship of the virulent YM parasite to 
other parasites in the 17X isolate remains obscure. The virulent (YM) and avirulent 
(17X) parasites have each been cloned; the growth characteristics of each clone 
conformed to that described for the parental type (Owen, 1994).
1.4 The host immune response to malaria parasites
The malaria parasite like other parasites has developed sophisticated strategies to adapt 
to its host and evade the attack of the immune system. Immunity to malaria has been 
studied in humans and the most appropriate murine models. Although the mechanisms 
that operate in the control of infections are very complex, and have not been clearly 
established, it is known that malaria parasites stimulate humoral and cell-mediated 
immune responses, both of which play a role in the protection against malaria parasite 
infection (Taylor-Robinson, 1995).
Protection induced by vaccination can be correlated with the production of specific 
antibody. However, T-cell mediated immunity may also be involved, with activation of 
macrophages as possible effector mechanisms with or without specific antibodies being 
involved. Hie production of cytokines such as interferon gamma (IFN-y) and tumour 
necrosis factor alpha (TNF-a) (Taylor-Robinson^ 1995) may also be important in 
stimulating B-cells to secrete antibody and in activating macrophages. Macrophages can 
act as effector cells in malaria by releasing cytotoxic substances such as reactive oxygen 
radicals and nitric oxide which destroy parasites within erythrocytes. This cytotoxic 
mechanism may be mediated through the release of TNF (lymphokine production) by 
macrophages, because it has been suggested that TNF can kill several species included 
P. falciparum in vitro. However the parasite sensitivity to TNF may differ in vivo 
(Taverne et al., 1986).
CD4^ T helper (Th) cells can be separated into two major subsets which mediate 
qualitatively distinct immune responses; for example, cell-mediated responses (Till) and 
humoral responses (Th2). A characteristic of murine malaria parasites is that primary 
infections with asexual erythrocytic forms generate a host protective immune response 
with a spectrum of Thl and Th2-type CD4* T-cells. The way in which CD4* T cells 
effect their protective role appears to be different in various murine models (Taylor- 
Robinson, 1995).
Butcher (1996) discusses models for malaria, and points out the fact that acquired 
resistance to malaria involves an initial phase of non-specific macrophage/neutrophil 
activation with concomitant increase in the concentration of TNF in serum. This may 
result in the characteristic symptoms and pathology such as high temperature and limited
parasite replication. However it is difficult to distinguish these effects from those caused 
by oxygen free radicals or other cytotoxic factors that may also be present. This process 
is associated with the host controlling parasite replication. It is followed by a rise m 
antibody levels and the gradual replacement of a Thl-cell type response by a Th2-cell 
dominated response, with further reduction in the parasite numbers. There is also 
evidence for macrophage activation in both humans and murine models during the early 
acute phase of infection, and the role of antibodies in subsequently controlling and 
eliminating parasites. In terms of humoral response, the antibody-mediated immunity 
takes time to become effective. This may be because parasite antigens show 
considerable diversity. This antigenic diversity induces a switch in the host immune 
response ( Butcher, 1996). Both polyclonal and monoclonal antibodies have been useful 
to identify protective protein antigens and to establish their physicochemical 
characteristics. The genes that encode these proteins have been cloned, sequenced and 
expressed in a variety of expression vectors.
Weidanz and Long (1988), found that splenic T cells from mice immune to P. yoelii^ as 
well as from non-immune mice, proliferated when exposed to parasitised erythrocytes or 
to lysates of these cells. The proliferative response of the T cells derived from immune 
mice occurred earlier than that of the T cells from non-immune mice. This result may 
reflect the presence of mitogemc factors in the crude preparations of malaria antigens 
used to stimulate lymphocyte culture in vitro. Others studies have shown that both 
murine and humans T cell lines and clones proliferate in responses to plasmodial antigens 
from different stages of tlie malaria parasite. These responses are antigen-specific and 
major histocompatibility complex (MHC)-restricted (Riley et al., 1991). Another
indication of specific T cells activation by malaria antigens is the expression of delayed- 
type hypersensitivity (DTH) in immunised mice when challenged with malaria antigens.
M alaria vaccine candidates
There are various proteins expressed at different stages of the life cycle that have been 
defined as targets of the immune response and potential vaccine candidates. For 
example, the circumsporozoite protein (CSP) on the surface of sporozoites, merozoite 
surface protein-1 and -2 (MSP-1 and MSP-2) and sexual stage antigens, such as a 48/45 
kDa gamete surface protein (Pfs48/45) and a 25 kDa zygote/ookinete surface protein 
(Pfs 25). Although many antigens can be shared between the different stages, it appears 
that immunity is species and stage specific; for example, immunisation with sporozoites 
does not protect against blood stage challenge and vice versa. Each vaccine strategy has 
certain limitations. For example, in the case of a vaccine targeted at sporozoites, it may 
prevent the initial infection but it would be ineffective against subsequent blood stages. 
Since a single sporozoite is capable of initiating a full-blown asexual blood stage 
parasitaemia, an anti-sporozoite vaccine may need to be 1 0 0 % effective to provide 
protection in individuals not previously exposed to malaria. Although a vaccine directed 
against the asexual blood stage may reduce or abolish clinical symptoms, it may have no 
effect on the development of the sexual stages and the transmission of the disease. A 
vaccine against the sexual stage of the parasite's life cycle would not protect the 
individual but may reduce transmission and the subsequent infection of others (Holder,
1993).
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Within the context of a pre-erythrocytic stage vaccine, CSP has been studied most 
intensively with the aim of developing a vaccine to prevent the initial infection. The 
identification of this antigen and the demonstration that a Mab specific to a central 
repetitive element ([Asn-Ala-Asn-Pro]n in P, falciparum, but different in different 
parasite species) within it could passively protect mice against sporozoites, formed the 
conceptual basis of the vaccine trials that have been carried out. Despite early problems 
with immunogenicity and limited evidence of protection, recent studies using RTS,S a 
hybrid CSP-Hepatitis B surface antigen particle expressed in yeast cells and mixed with a 
powerful adjuvant, have shown impressive levels of CSP-specific antibody and very 
good protection against sporozoite challenge in volunteers (Stoute et al., 1997).
The proteins that have been identified as possible targets of immune responses which 
inhibit erythrocyte invasion have been placed in three groups (Holder, 1996), a 
classification that is based on the location of the proteins. These proteins are (1) 
merozoite surface proteins (MSPs), (2) soluble proteins that may be loosely associated 
with the merozoite surface, and (3) proteins in the apical organelles. These groups 
include (1) merozoite surface proteins-1 and -2 (MSP-land MSP-2); (2) serine repeat 
antigen (SERA), secreted polymorphic antigen associated with merozoites 
(SPAM/MSP-3), glutamate acid-rich protein (GLURP), acidic basic repeat antigen 
(ABRA), and S-antigen; and (3) proteins in the apical organelles, comprised of 
microneme and rhoptry proteins. Within the microneme is the P. falciparum 175 kDa 
erythrocyte binding antigen (EBA-175) that appears to bind to the host molecule 
glycophorin A, and is related to the Duffy-blood group binding protein of P. vivar. The 
rhoptry protein group includes apical membrane antigen 1 (AMA-1) and rhoptry- 
associated proteins -1 and -2 (RAP-1 and RAP-2).
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Hie characteristics of these proteins are outlined briefly below, except for those of MSP- 
1 , which is described in detail later in this chapter:
MSP-2: Hiis is a 43- to 56-kDa protein on the merozoite surface, and it is recognised by 
antibodies that inhibit P. falciparum growth in vitro (Fenton et al., 1991; Ramasamy et 
al., 1990). Hie protein is anchored on the surface by a glycosyl phosphatidyl inositol 
but, unlike the 19 kDa fragment of MSP-1 it does not appear to be carried into the 
erythrocyte at invasion. For this protein there are two families that are largely defined by 
the highly variable repetitive and non-repetitive variable regions; one is typified by the 
sequence in the FC27 strain and the other by the sequence in the ICI and 3D7 strains. 
MSP-2 is a vaccine candidate because of its location and because Mabs reactive with 
MSP-2 inhibit parasite growth in vitro. Hie sequence and antigenic diversity also 
suggest that MSP-2 is under immunological pressure. A vaccine based on this protein 
may include either a structure conserved between the families or two structures 
representative of the two forms.
SERA: Hie serine repeat antigen, also known as serine-rich protein, p i 13, pl26, or 
p i40; is a soluble protein synthesised by the late-erythrocytic-stage parasite and secreted 
into the parasitophorous vacuole. At the end of schizogony, the protein is cleaved into 
50 and 73 kDa fragments. N-terminal sequencing showed that the 73-kDa fragment is 
composed of a 47-kDa polypeptide from the N-terminus disulphide linked to an 18-kDa 
fragment from C terminus of SERA Hie evidence that this antigen is a potential vaccine 
candidate has been obtained largely from direct immunisation data, although SERA- 
specific growth inhibitory Mabs have been described, and the protein has been shown in
1 2
antibody-merozoite aggregates. Two recombinant antigens, SERA 1 and SERA N have 
been expressed in yeast and tested in Aotus immunisation studies. Both proteins are 
recognised by a Mab that blocks parasite invasion (Barr et al., 1991; Iselburg et al., 
1991).
SPAM/MSP-3: This antigen was described recently and identified by purified hunian 
IgG antibodies active in an in vitro antibody dependent cell inhibition (ADCI) assay. 
Concurrently, SPAM, a protein with the same partial sequence was also reported 
(Oeuvray et al., 1993 & 1994). This is a soluble protein only loosely associated with the 
merozoite surface.
GLURP: Glutamate-rich protein has been examined extensively in field studies, but there 
are no in vivo or in vitro studies to implicate it as a target of protective immunity. The 
protein has an apparent molecular mass of 220 kDa, and it is expressed in liver and 
asexual blood stages. This antigen is considered to be a vaccine candidate based on its 
location, and because sero-epidemiological studies have shown a correlation between 
antibody response and low parasitaemia (Dziegiel et al.,1993).
ABRA: Acidic basic repeat antigen is a soluble protein of the parasitophorous vacuole 
and it is also found in agglutinated clusters of merozoites. This protein has been poorly 
studied, and the evidence to support its use a vaccine candidate is weak.
S-antigcn: S-antigens are highly diverse, heat-stable, soluble proteins of the 
parasitophorous vacuole. Four families of S-antigens have been defined based on the N- 
and C-terminal sequences. The protein can be cross-liked to MSP-1 and therefore may
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be loosely associated with the merozoite surface. An q>ecific Mab against this protein 
inhibits parasite growth in vitro (Saul et at., 1995), but there is no other evidence that S- 
antigens are involved in protective immunity against the merozoite stage.
Erythrocyte binding proteins located in the micronemes: The parasite's ability to invade 
the erythrocytes depends on the host, the expression of particular molecules on the 
erythrocyte surface, and the age of the erythrocyte. Parasite protein binding to specific 
molecules of the erythrocytes surface is an integral part of the invasion process (Mitchell 
et al., 1986). A 175-kDa P. falciparum erythrocyte-binding protein (EBA 175) is a 
sialic acid-binding protein and may be targeted by a vaccine strategy designed to 
interfere with specific receptor-ligand interactions.
Rhoptry proteins: The rhoptry organelles contaiu a number of proteins, all with unknown 
function, but some implicated as targets of protective immunity. There is 
compartmentalisatlon within the rhoptries, with different proteins not being uniformly 
distributed throughout. A 225-kDa protein derived from a 240-kDa precursor is located 
in the necks of rhoptries, and a similar localisation has been described for apical 
membrane antigen 1 (AMA-1). Two macromolecular complexes have been identified in 
the body of the rhoptries (Doury et al. 1994): a high-molecular-maSs complex of 150, 
130 and 110 kDa proteins and a low-molecular-mass complex of rhoptry-associated 
protein 1 (RAP-1) and RAP-2. These proteins are associated with membranous 
structures released from merozoites and after invasion they are associated with the 
parasitophorous vacuole membrane parasite plasma membrane (Crewther et al., 1990). 
Immunofluorescence studies and radiolabehng indicate that AMA-1 is also located on
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the merozoite surface at the apical end of the parasite (Thomas et al. 1990 & Waters et 
al., 1990).
An effective vaccine may require a mixture of several elements from different antigens of 
different stages, and it will be a costly and formidable task to identify and test all the 
candidates for inclusion in such a cocktail (Holder, 1993).
1.6 Merozoite Surface Protein-1: structure, processing and function
MSP-1 is a high-molecular-mass protein synthesised as a precursor during schizogony 
and found on the surface of the merozoite as a complex of fragments derived by 
proteolytic processing of the precursor (Holder 1988). In P. falciparum, MSP-1 is al95- 
200 kDa protein. The protein has also been given a number of different names, including 
the precursor to major merozoite surface antigen (PMMSA), polymorphic surface 
antigen (PSA), glycoprotein 195 (gp 195) and merozoite surface antigen- 1 (MSA-1). 
MSP-1 has been found in all malaria species, including P. vivax (Pv 200) and the rodent 
malaria parasites, such as P. yoelii (a 230 kDa protein) and P. chabaudi (a 199 kDa 
protein) (Diggs et al., 1993).
MSP-1 is a precursor protein for a number of smaller polypeptides found on the blood- 
stage merozoite (Holder & Freeman, 1984; McBride & Heidrich, 1987). The proteolytic 
processing of P. falciparum MSP-1 has been studied in most detail, but similar 
proteolytic cleavage appears to occur in other species (David et al., 1984; O'Dea et al.,
1995). The processing occurs in two steps. Primary processing involves cleavage of the 
precursor to give four fragments of approximately 83, 30, 38 and 42kDa (called MSP-
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l 83, MSP-I30, MSP-138 and MSP-I42). These fragments are present in a complex on the 
merozoite surface, attached by the glycosyl phosphatidyl inositol-anchored C-terminal 42 
kDa fragment. At the time of invasion, secondary processing of the membrane-bound 42 
kDa fragment occurs between a leucine and an asparagine residue to produces a N- 
terminal cleavage product of 33kDa and a C-terminal 19 kDa fragment. The 33kDa 
fragment (MSP-I33) is shed from the merozoite surface as part of a soluble complex with 
other fragments of MSP-1 and the 19 kDa fragment (MSP-119) remains membrane bound 
and is carried into the invaded erythrocyte, where it can be detected in early ring stage 
parasites (Blackman et al., 1990). The enzyme involved in this secondary cleavage is a 
calcium-dependent serine protease (Blackman & Holder, 1992). The importance of the 
primary processing stiU needs to be elucidated. However, in successfully invaded 
parasites the enzymatic processing goes to completion.
The amino acid sequence of MSP-1 corresponding to MSP-119 resembles two EGF-like 
motifs (Blackman et al., 1991). The sequence contains a series of cysteine residues which 
are highly conserved. Comparison of MSP-1 sequences from different malaria parasite 
species, reveals the conservation of 1 0  cysteine residues and the preservation of their 
relative positions within the C-terminal region of molecule (Daly et al., 1992). The 
arrangement of the cysteines suggests that they form disulphide bonds within each EGF- 
like motif and thereby stabilise the 3-dimensional structure of the protein. Single-site 
substitutions may have profound effects on this conformational structure which may 
consequently affect the accessibility of antibodies to key regions of molecule (Holder & 
Blackman, 1994).
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Several authors have discussed the function of MSP-1. The precursor protein has been 
reported to bind to sialic acid on erythrocytes (Perkins & Rocco, 1988). Cooper (1993) 
suggests that MSP-1 is involved in the invasion of erythrocytes, because antibodies 
specific for MSP-1  can block invasion in vitro. Holder and Blackman (1994) suggested 
that MSP-1 could be involved in the initial recognition of red blood cells, but that this 
interaction is weak. They also suggested that the fragment retained on the parasite 
surface may act like other membrane-bound growth factors and interact with a specific 
receptor protein, perhaps on the red blood cell surface. Alternatively the fragment could 
also have other biochemical functions, such as a signal-transduction system leading to 
the activation of specific protein kinases, to communicate to the cell that successful 
invasion has cxeurred and differentiation should continue.
1.7 Expression, antigenicity and immunogenicity of recombinant MSP-1.
MSP-1 purified from the parasite has been shown to induce partial or complete 
protection against challenge infection of malaria parasites in animal mcxiels (Diggs et al.,
1993). Therefore, this protein is considered as one of the best candidates for an anti- 
malarial vaccine, and extensive research is being carried out in order to produce a MSP- 
1 recombinant protein, which maintains the conformation of the native antigen. Several 
studies have been carried out to produce parts of MSP-1 in heterologous expression 
systems so that their antigenicity and immunogenicity can be studied. The C-terminal 
region of MSP-1 protein has been produced using the eukaryotic baculovirus insect cell 
expression system. A recombinant protein is produced which has a similar conformation 
to that of native MSP-1 (Murphy et al., 1990; Chang et al., 1992). Recently the 19kDa 
C-terminal fragment has been expressed in recombinant bacteria and yeast (Chappel &
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Holder, 1993; Kaslow et al., 1994; Burghaus & Holder, 1994). The integrity of 
disulphide-constrained epitopes, defined by antibodies reactive with the native protein, is 
intact in the recombinant proteins. Reduction and alkylation of P. falciparum MSP-119 
abolishes its recognition by Mabs and polyclonal antibodies; this treatment of native 
MSP-1 also abolishes its ability to bind these antibodies. Epitopes of inhibitory Mabs are 
either present on individual EGF-Hke motifs or require both motifs in order to be 
present. Mc^t of the antibody-binding sites in MSP-119 appear to be conformational; the 
two EGF-Hke domains are required for the formation of dominant epitopes (Holder,
1996).
1.8 The immune response to MSP-1
MSP-1 is considered to be a vaccine candidate. This is based on an understanding of the 
biology of the parasite, such as the production of MSP-119 by a proteolytic process and 
the retention of this fragment on the intraceUular ring stage, and experimental studies in 
which the MSP-1 molecule purified from the parasite, was able to induce protection in 
animals models. Antibodies to the 42 kDa fragment of MSP-1 and, in particular that part 
which comprises MSP-119 , inhibit parasite development in vitro, possibly by inhibiting 
protease cleavage (Blackman et al., 1994). Immunisation with MSP-1 purified from 
extracts of P. falciparum either partiaUy (EtHnger et al., 1991) or completely (Siddiqui et 
al., 1987) protected against blood stage parasite chaUenge in primate models. Partial 
protection has also been obtained with peptides or recombinant proteins. The locations 
of epitopes recognised by Mabs with a biological function have also been identified; 
some antibodies against MSP-1 are known to inhibit merozoite invasion of erythrocytes 
in vitro (Pirson & Perkins, 1985; Blackman et al., 1990; Cooper et al., 1992). Cooper
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and colleagues (1992) determined the antibody bmding sites for a panel of Mabs against 
the P. falciparum MSP-1. The epitopes were mapped by using the naturally occurring 
processing fragments, by chemical cleavage of the protein, and by comparison of the 
isolate-specificity of binding with known sequence variation. The Mabs also gave an 
indication of the relative antigenicity of different parts of the protein, this analysis 
suggested that C-terminal region contains an immunodominant domain. The 19 kDa 
polypeptide is the target of inhibitory antibodies (Blackman et al., 1990; Chappel & 
Holder, 1993). There are multiple mechanisms by which antibodies to C-terminal region 
of MSP-1 may inhibit parasites, including inhibition of proteolytic processing of MSP-1 
(Blackman et al., 1994).
Immunisation studies using the P. yoelii in mice model have suggested that MSP-1, and 
in particular the C-terminal region of MSP-1, is able to induce protective immune 
responses. Immunisation with native P. yoelii MSP-1 protects mice against challenge 
infection (Holder & Freeman, 1981 ). Immunity is passively transferred with a Mab 
against an epitope in the EGF-like motifs of P. yoelii MSP-1 (Majarian et al., 1984; 
Bums et al., 1989). In recent years, immunisation with recombinant proteins based on 
the 19 kDa fragment at the C-terminus of P. yoelii MSP-1 gave very good protection 
against parasite challenge; this protection was mediated by antibodies and required both 
EGF-domains and the conformational structure of protein to be preserved (Daly & Long, 
1993, Ling et al., 1994; Ling et al., 1995). Direct analysis of the functional response in 
the P. yoelii model have confirmed that the protective response induced by 
hnmunisation with recombinant MSP-119 is mediated by antibodies. This is supported by 
the kinetics of the effector response, and passive immunisation studies with purified 
immunoglobulin or immune serum, indicating a significant role for humoral immunity in
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protection (Daly & Long, 1995). Also, it was shown that immunisation with reduced and 
alkylated protein did not induce an antibody response to the native protein (Ling et al.,
1994).
Hui and colleagues demonstrated that the immunogenicity of the C-terminal 19-kDa 
fragment of Pf MSP-1 expressed in yeast (YMSPl 19) was dependent on the mouse strain 
and the adjuvant formulation. They suggested that adjuvants may modulate the 
immunogenicity of MSP-119 in genetically diverse populations. This observation and 
other experiments suggest that T helper epitope(s) on MSPl were effective in helping to 
producing anti-MSPl antibodies. They hypothesised that the nature and/or specificity of 
T helper epitopes may be crucial in inducing a parasite inhibitory, anti-MSP-1 antibody 
response. Hence, the presence of these epitopes may determine the efficacy of an MSP-1 
vaccine (Hui et al., 1994). The antibody response induced in humans will need to be 
studied in great detail.
Recently, Holder and Riley (1996) reviewed what is known about the human immune 
response to MSP-1. Li epidemiological studies both cross-sectional and longitudinal 
surveys have shown that antibodies and T-cell and cytokine responses to certain parts of 
MSP-1, in particular the C-terminus, are associated with a reduced susceptibility to 
clinical malaria. Li the work of Udhayakumar et al.(1995), it was found that T-cell 
proliferative responses were stimulated much more by peptides from the N-terminus of 
MSP-142, suggesting better T-cell recognition of linear peptides, rather than those in 
highly disulphide bonded regions. This is supported by the observation that reduction 
and alkylation of antigens increases proteolytic processing and presentation of 
immunogenic peptides bound to MHC class H. Experiments with synthetic peptides may
2 0
not be the most appropriate way to assess the T-cell response, although the use of 
peptides in T-cell assays obviates the need for processing and presentation of the native 
molecule if the peptides bind directly to HLA molecules.
I S  Aim of the project
The results of the protection studies in mice after immunisation with recombinant MSP- 
l i9 have increased interest in the potential of this antigen as a vaccine candidate. 
Monoclonal antibodies (Mabs) are good tools with which to study MSP-1 because they 
may recognise important epitopes and inhibit parasite invasion in vivo and in vitro. 
However, there are few Mabs that can be used in the P. yoelii murine model and it was 
therefore necessary to produce more Mabs against P. yoelii MSP-1 for further studies.
My project was the production and detailed characterisation of Mabs to the C-terminus 
of MSP-1, with the particular goal of defining the epitopes recognised by antibodies 
capable of inhibiting invasion in vivo.
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Figure 1.1.
The life cycle of Plasmodium. In this diagram is shown the sequence of the four phases 
of the life cycle. The first asexual phase takes place in an Anopheles mosquito, leading to 
the formation of sporozoites. The second and the third asexual phases (liver and 
erythrocytic schizogony, respectively) occur in a vertebrate host, in this case a human. 
The sexual phase is initiated in the mosquito gut from gametocytes ingested from an 
infected individual.
Source: The Trustees of Wellcome Trust.
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CHAPTER 2: MATERIALS AND METHODS
2.1 The malaria parasite
A clone of Plasmodium yoelii yoelii YM was used in all experiments (Yoeli et al., 1975). 
The parasites were maintained as a frozen stock in liquid nitrogen and passaged by 
intraperitoneal inoculation into adult BALB/c mice. Four to 5 days after inoculation, 
blood was harvested from the brachial plexus of infected mice, into a solution containing 
50 U of preservative-free sodium heparin (Sayles & Wassom, 1988). Parasitaemia was 
measured by microscopic examination of thin blood smears stained with Giemsa’s 
reagent. At low levels of infection, the number of parasites in 50 fields each containing 
250 erythrocytes was counted. At high levels of infection (more than 10 parasites per 
field) the number of parasites in 200 red blood cells was counted. In each case the 
percentage parasitaemia ([the number of parasite-infected cells counted /total number of 
erythrocytes counted] x 100%) was determined. Animals were considered to be clear of 
infection if no parasites could be detected on thin smears.
2. 2 Expression and preparation of recombinant protein containing the C-terminal 
amino acid sequence of Plasmodium yoelii MSP-1
P. yoelii MSP-1 sequences were expressed iu Escherichia coli using the plasmid 
pGEX3x. The pGEX plasmids are designed to induce high level intracellular expression 
of a gene fragment as a fusion protein at the C-terminus of Schistosoma japonicum 
glutathione S-transferase (GST) (Smith & Johnson 1988). Tlie GST-MSPl fusion
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proteins were used to immunise mice and as antigens to analyse the specificity of 
monoclonal antibodies (Mabs).
The DNA sequence of the C-terminal 19 kDa fragment of P. yoelii YM MSP-1 (MSP- 
I19) which contains the two EGF-like motifs (residues 1649 to 1754 in the amino acid 
sequence numbered according to Lewis, 1989) was inserted into the E. coli expression 
vector pGex3x (Ling et al., 1994). Expression of the GST-MSPl 19 fusion protein was 
induced and then the bacterial cells were harvested. A soluble lysate of the cells was 
prepared and passed through a column of glutathione-agarose. After extensive washing 
of the column the GST fusion protein was eluted with 8  M urea (Ling et al., 1994). 
Fractions containing the recombinant protein were pooled and then dialysed extensively 
against phosphate buffered saline (PBS) in order to remove the urea. A similar protocol 
was used for the expression of each individual EGF-like motif of MSP-1 (MSPIEGFI is 
the first motif and MSP1EGF2 is the second motif) as fusion proteins with GST (Ling et 
al., 1995). The DNA sequence coding for MSP-119 was also amplified from genomic 
DNA of P. yoelii 265BY and expressed as a GST fusion protein. The plasmids were 
kindly provided by Miss Irene Ling.
Colonies of E. coli containing plasmid were initially grown overnight at 37°C on an 
agar plate containing 50 jug/ml ampicülin. One colony was picked and transferred to 10 
ml of L-broth supplemented with 0.1 mg/ml ampicilHn. The culture was then incubated 
for 12 or 24 hr at 37°C with continuous shaking. After this time, the cells were 
transferred to 100 ml of medium, and 60pg/ml of isopropyl P-D-thiogalactoside (EPTG) 
were added to induce protein expression. After incubation at 37°C for 1-2 h with 
continuous shaking the cells were harvested by centrifugation (7,000g for 10 min at
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4°C) to sediment the cells. The supernatant was discarded and the bacterial cell pellet 
was resuspended in 10 ml of suspension buffer (25 mM Tris-HCl, pH 8.0; 1 mM EDTA; 
0.2 % Nonidet P40 (v/v); and 100 mM phenyl methyl sulphonyl fluoride [PMSF]) and 
then the cells were lysed by sonication. DNA was then digested by adding 20 pi DNAse 
(10 mg/ml) and 20 pi IM MgS0 4  to 10 ml of the bacterial cell lysate for 2 hrs. Cellular 
debris were removed from the lysate by centrifugation (15,(X)0g) for 1 hrs. The cleared 
lysate was then applied slowly to a glutathione-Sepharose 4B column (Sigma). After the 
bacterial lysate had passed through the column, the column was washed with KXhnl of 
suspension buffer. This was followed with a further wash with 100ml of PBS. The GST- 
fusion protein was eluted with 8 M urea in 50mM Tris-HCl, pH 7.5, collecting fractions 
of 1ml. The fractions were monitored for the presence of GST-fusion protein by 
electrophoresing a small sample on SDS-PAGE (see Section 2. 12). The peak fractions 
containing most of the protein of interest were pooled and then dialysed against PBS.
The yield of fusion protein was estimated by measuring the Absorbance of the protein 
solution at 280 nm and calculating the concentration of the protein by use of the formula: 
an Absorbance of 1.0 at 280nm (1 cm path length) corresponds to a protein 
concentration of 0.5 mg/ml.
2 .3  Preparation of recombinant M S P - I 1 9
Recombinant MSP-119 was obtained by treatment of the GST-MSPl 19 fusion protein 
with Factor Xa protease (Abath & Simpson, 1990). The fusion protein was bound to 
glutathione-agarose and then treated with Factor Xa protease (from Boehringer 
Mannheim), which cleaves at a unique site between the GST-carrier and the recombinant
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MSP-119. After cleavage the GST remains bound to the column and the released soluble 
MSP-119 can be eluted and purified. The recombinant MSP-119 was used to develop an 
enzyme-hnked immunosorbent assay (ELISA) for the initial screening of hybridoma 
supernatants and for the characterisation of Mabs.
To produce recombinant MSP-119 a batch of GST-MSPl 19 was bound to glutathione- 
agarose in a column. Factor Xa was dissolved in 30pl of water and added to 4ml of 
cleavage buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, ImM CaCb) to give a final 
concentration of 50pg/ml. The enzyme solution was then allowed to permeate the 
column, which was then sealed and incubated overnight at 4°C, in order to allow 
digestion of the GST fusion protein. The released MSP-119 was then eluted from the 
column, leaving GST remaining bound to the matrix. GST was then eluted from the 
column with 8 M urea in 50mM Tris-HCl, pH 7.5, and following this elution the column 
was washed with PBS. Both proteins were dialysed against PBS and the concentration 
of proteins was measured as described above. The purified proteins were analysed by 
SDS-PAGE on 15% polyacrylamide gels according to the method of Laemmli (1970), as 
described in Section 2. 12.
2.4 Reduction and Alkylation of GST-MSPI1 9
In order to determine whether or not the epitopes recognised by Mabs were dependent 
upon disulphide bonds, GST-MSPl 19 was reduced and alkylated with sodium 
iodoacetate prior to analysis by western blotting. Briefly, 500pl of the GST-MSPl 19 
solution was treated by addition of dithiothreitol (DTT) to 50mM, and incubation for 30 
minutes at room temperature, followed by addition of sodium iodoacetate to 200mM and
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a further incubation for 15 minutes at room temperature, in a solution adjusted to pH 8.5 
with NaOH. The protein was then dialysed extensively against PBS at 4°C (Ling et al.,
1994) prior to use for immunoblotting as described in Section 2. 13.
2.5  Mouse immunisation protocol
A group of five 6 -week old BALB/c female mice were each immunised intraperitoneaUy 
with 0.13 mg GST-MSPl 19 recombinant protein in Freund’s complete adjuvant (FCA). 
The response was boosted by three further injections of the protein in Freund’s 
incomplete adjuvant (FIA) 7, 21 ^ d  35 days later. On days 28 and 80 after the first 
immunisation, blood samples were taken from the tail to determine the level of serum 
antibodies against MSP-119 by ELISA. If the ELISA titre was at least 1:3200, the spleen 
of the mouse was removed and used to prepare hybridomas.
In a second series of experiments, mice that had been passively immunised with 
monoclonal antibodies, challenged with parasites and then had cleared the infection, 
were inoculated on three occasions with 5 xlO* parasitised erythrocytes prior to 
harvesting their spleens to prepare hybridomas.
2. 6  Preparation of monoclonal antibodies
Spleen cells from mice immunised with GST-MSPl 19, or by parasite infection, were 
fused with SP2/0 Agl4 mouse myeloma cells in the presence of 50 % polyethylene 
glycol (PEG). The cell ratio was 4:1 (8x10^ spleen cells to 2x10^ myeloma cells). In 
general, the fusion protocol was as described by Harlow and Lane (1988). Before fusion
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with spleen cells, the myeloma cells were cultured in the presence of 8 -azaguanine to 
ensure their sensitivity to the hypoxanthine-aminopterine thymidine (HAT) selective 
medium, and then five days prior to cell fusion, they were transferred to a medium 
without 8 -azaguanine. At the time of fusion a high cell viability is required and this was 
verified by the trypan blue exclusion method, in which non-viable cells acquire a blue 
cytoplasm and viable cells retain an unstained cytoplasm. After the fusion, the suspension 
of hybridoma cells was dispensed into 96-well culture plates (Nunclon TC microwell 
plates) using l(X)pl/well in a diluent of HAT-supplemented R PM I1640 medium. After 
1 0  days of culture, the supernatant medium from each well was screened for antibody 
reactivity by ELISA with the recombinant MSP-119 (as described in Section 2. 7.1). 
Supernatants from the positive wells were then tested further for the presence of 
antibodies reacting with the parasite by using the indirect immunofluorescence assay 
(IFA; Voiler & O'Neill, 1971), as described in Section 2. 7. 2).
The hybridoma cells from weUs containing reactive antibody were cloned at least three 
times by using the limiting dilution method in hypoxanthine-thymidine medium (HT), 
following the protocol described by Harlow and Lane (1988). A soluble hybridoma 
growth factor (HGF) supplement (Immune System) was used during the hybridoma 
cloning steps and afterwards during the expansion of cell lines from the microwells. The 
hybridomas were grown in RPMI 1640 complete medium supplemented with 20% (v/v) 
foetal calf serum (PCS) and 1 % glutamine. The number of hybridomas that lost their 
ability to produce antibodies decreased with successive cloning and all the cultures that 
remained antibody positive cultures after the recloning procedure were considered 
stable. To maintain samples of the hybridoma cells at each cloning step they were frozen
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at -70°C in RPMI complete medium containing 10% dimethylsulphoxide (DMSO) and 
50% PCS.
2. 7 Screens to detect MSP-1 specific monoclonal antibodies 
2. 7.1 Enzyme-linked Immunosorbent Assay (ELISA)
The ELISA test was used for the initial screen to detect hybridomas secreting 
MSP-119 specific antibodies. Ninety six well plates (Immulon 4 from Dynatech) were 
coated with lOOpl of antigen solution (recombinant MSP-119) per well, using 1 pl/ml of 
the antigen solution diluted in coating buffer (0.1 M sodium carbonate/bicarbonate pH 
9.6, containing 0.02% sodium azide). Plates were then incubated overnight at 4°C and 
washed three times (3X) with PBS containing 0.05% Tween 20 (PBS/T). Plates were 
then blocked by addition of PBS containing 1% bovine serum albumin (BSA) for 30 
minutes at room temperature, followed by further washing with PBS (3X). One hundred 
microlitres of the supernatant from wells containing hybridomas were added to each well 
and incubated at 37°C for 1 hour. The plates were then washed 3X with PBS and 
lOOjLil/weU of horseradish peroxidase-conjugated (HRP-) rabbit anti-mouse polyvalent 
immunoglobulins (IgG, IgA, and IgM-spccific, Sigma) were added at a 1:KXK) dilution. 
After incubation for 1 hour at 37°C the plates were washed again with PBS. Binding of 
the conjugate to bound antibody was detected by the addition of lOOpl of o- 
phenylenediamine dihydrochloride (OPD, Sigma) as a 0.4mg/ml solution in 0.05M 
phosphate-citrate buffer, pH 5.0 containing 0.03% sodium perborate. The reaction was 
stopped by addition of 50pl 2M H2SO4 per well. The plates were read in a Htertek
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Multiscan MCC/340, using Titer-soft Software (Flow) to measure the Absorbance at 
492 nm.
A mouse polyclonal serum against recombinant MSP-119 of P. yoelii was used as a 
positive control and normal mouse serum (NMS) was used as a negative control.
2 .7 .2  Indirect Immunofluorescence Assay (IFA)
After the initial screening by ELISA, supernatants from the positive wells were tested by 
IFA to detect antibody reaction with the parasite. The antigen used in the preparation of 
the IFA slides was a blood film of erythrocytes containing P. yoelii YM, and obtained 
from infected mice with a parasitaemia of about 30%. The mice were bled into Kreb’s 
glucose solution (KGS) containing 5% heparin and then the blood was passed through a 
column of Fibrous Cellulose Power (CF-11) to remove the leukocytes (Richards & 
Williams 1973). The erythrocytes were pelleted by centrifugation at 19,000 rpm (IFC 
Centra-4B centrifuge), and then resuspended at a dilution of 1:20. A volume of lOpl of 
this antigen was added to each well of an IFA slide (Dynatech), the slides were air dried 
and then fixed by immersion in acetone. The IFA procedure was performed as described 
by VoUer and O’Neil (1971). Hybridoma supernatants, or solutions of purified Mab were 
incubated with the acetone-fixed P. yoelii infected erythrocytes in a humid chamber for 1 
hour, then the slides were washed with PBS and incubated with a secondary antibody for 
1 hour. The secondary antibody was fluorescein isothiocyanate-conjugated goat anti­
mouse immunoglobulin (FTTC-conjugate from Sigma) diluted 1:KXK) in PBS. Slides 
were washed again, dried, covered with 80% (v/v) glycerol in PBS and examined using a 
fluorescence microscope (Leitz, Germany) to detect the binding of antibody. The titre of
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samples was determined; the values represent the last dilution of the test Mab solution 
which yielded visually detectable fluorescence.
The titre of antibodies in the sera of mice after passive immunisation was also determined 
by IFA. Serum samples were diluted in two-fold steps, starting at a dilution 1:50 in PBS.
2.8 Purification of monoclonal antibodies by Protein G chromatography
Monoclonal antibodies were purified by Protein G Sepharose 4 Fast Flow (Pharmacia ; 
Akerstrom et al., 1985) according to the manufacturer’s recommendations. The matrix 
binds all mouse IgGs (IgGl, IgG2a, IgG2b and IgG3) at 5mg antibody per ml of 
swollen gel. Protein G Sepharose is supplied pre-swoUen in 20% ethanol, therefore the 
gel was washed with binding buffer (20mM sodium phosphate, pH 7.0) to remove the 
ethanol and then packed into a column and equilibrated with binding buffer at room 
temperature, using 2 0 0  ml of binding buffer at flow rate of 60ml/hour. After the sample 
was loaded, the column was washed extensively and then bound IgG was eluted with 15 
ml of 0.1 M glycine-HCl buffer, pH 2.5-3.0. In order to neutralise the eluted IgG solution 
a few drops of IM Tris-HCl, pH 9.0 were added and then it was dialysed against PBS.
The purity of the eluted Mabs was analysed by SDS-PAGE (Section 2. 12) after 
reduction to detect the presence of light (25 kDa) and heavy (50 kDa) chains.
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2. 9 Passive Immunisation with Mabs and parasite challenge
Mice were passively immunised with purified Mabs to investigate their effect on the 
course of a parasite infection. Female BALB/c mice from 8  weeks of age bred under 
specific pathogen-free conditions were obtained from the National Institute for Medical 
Research SPF Unit. Groups of 3-10 mice were inoculated on three occasions by 
intrapeiitoneal injection with purified Mabs (0.5mg/injection; a total of 1.5mg 
IgG/mouse). The Mabs were administered one day before, one day after and on the day 
of a challenge infection. The parasite used for challenge was P. yoelii YM which causes 
a lethal fulminating infection in these mice. The parasite stock, stored at -70°C, was 
thawed and then passaged once in a BALB/c mouse before use. The parasite challenge 
was administrated by intravenous (i.v.) injection into the lateral vein of the tail, using 
5x10^ parasitised red blood cells (PRBC) per mouse. Parasitaemia was then assessed 
daüy on blood films stained with Giemsa’s reagent
2. 10 Determination of antibody isotype and subclass by ELISA and 
Immunodiffusion (ID)
The antibody isotype or subclass was determined by double diffusion in agar 
(Ouchterlony, 1958), A solution of 1 % agarose in PBS was prepared and using a pipette, 
5ml was applied onto a glass slide. The agar was allowed to solidify, wells were cut out, 
and then the slide was stored in a humidified chamber at 4°C. Ten microlitres of the Mab 
(0.5mg/ml) to be tested were placed in a centre well and 5pl of isolypc or subclass 
specific antibodies (Goat anti-Mouse IgGl, IgG2a, IgG2b, IgG3, IgM and IgA) were
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placed in surrounding peripheral wells. After 48 hours incubation in the humidified 
chamber at 4°C, a reaction was detected by the presence of a precipitation band.
The subclasses of the Mabs were confirmed by using a capture ELISA and an indirect 
ELISA with an isotyping kit from Sigma. The capture ELISA test was carried out 
according to the manufacturer’s recommendations. The subclass specific antibodies were 
diluted 1:1000 in PBS and lOOpl of each were dispensed into 2 wells of a microtitre 
plate (Immulon 4 fiom Dynatech) and incubated for 1 hour at 37°C. The plates were 
washed 3X with PBS/T, then lOOpl of each Mab (5jLig/ml) to be tested were dispensed 
into each well and incubated for 1 hour at 37°C. The Mab solution was then removed 
and the plates were washed. Peroxidase-conjugated Goat anti-Mouse IgG (Fab Specific) 
antibody was diluted 1:600 in PBS/T and lOOpl added to each test sample and the plates 
were incubated for 30 minutes at 37°C. The conjugate was removed and the plates were 
washed again. Hie plates were developed with lOOfil of OPD (0.4mg/ml in 0.05M 
phosphate-citrate buffer, pH 5.0 containing 0.03% sodium perborate), then the reaction 
was stopped and the Absorbance measured as described in Section 2.7.1.
In the indirect ELISA, Mabs to be tested were diluted tolpg/ml in PBS, dispensed into 
wells of a microtitre plate, and incubated for 1 hour at 37°C. The coated plates were 
washed 3X, then subclass specific antibodies diluted 1:1000 in PBS were dispensed to 
each well (lOOpl) in duplicate and incubated for 30 minutes at room temperature. The 
plates were washed again and 100 pi detection conjugate (diluted 1:5000) was added. 
After a further incubation for 30 minutes at room temperature the plates were washed 
again. Finally, the substrate was added and after colour development the Absorbance 
was measured.
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2.11 Biotinylatîon of Mabs and their use in a Competitive ELISA
Mabs were bdotinylated using Siilfo-NHS-Biotin (Pierce) as recommended by the 
manufacturer, for use in a competition ELISA together with an unlabelled second Mab.
To carry out the competition experiments the wells of 96-well microplates (Dynatech 
Immulon-4) were coated with Ipg/ml of antigen (recombinant MSP-119) as described in 
Section 2 .1 . 1. The excess protein binding sites in the wells were then blocked by the 
addition of 1% of bovine serum albumin in PBS. One hundred microlitres of a solution of 
unlabelled Mab were added to each well and incubated for 1 hr at 37°C, the wells were 
washed 3  times with washing buffer, and then 1 0 0  pi of a solution of the biotinylated 
Mab were added and incubated for 1 h at 37°C. The wells were washed again 3 times 
and then incubated with 100 pi of 10 pg/ml Streptavidin-Horse Radish Peroxidase 
conjugate for 1 h at 37 °C. Finally the plates were washed 3 times, followed by addition 
of KM) pi OPD substrate per well. The colour reaction was allowed to develop and then 
stopped by thé addition of 50 pi of IM sulphuric acid per well, and the Absorbance was 
read at 492 nm.
Statistical calculations were performed using GraphPad Prism® software. Comparisons of 
the mean Absorbance values between the different Mabs evaluated by competition 
ELISA were made using the Kruskal-Wallis analysis of variance. The Kruskal-Wallis test is 
a non-parametric test that can be used to compare three or more independent groups. 
The P value addresses this question: If the populations do have the same median, what is 
the chance that random sampling would result in medians as far apart as those observed
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in the experiment? If the P value is 0.05, it means that there is a 5% chance of observing 
a difference as large as that observed even if the two population means are identical. 
Therefore, there is a 95% probability that the difference observed reflects a real 
difference between populations and a 5% probability that the difference is due to 
chance. The P value is compared with a threshold value, (usually P< 0.05). If the P value 
is less than the threshold, the difference is statistically significant, but if the P value is 
greater than the threshold, the difference is not statistically significant (Glanztz, 1997).
2.12 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
Analysis of the purified recombinant proteins and Mabs was done by SDS-PAGE on 
15% or 12.5% polyacrylamide gels (Laemmli, 1970). Hie protein samples were 
solubilised in SDS sample buffer (0.15M Tris-Cl, pH 6 .8 , 4.6% SDS, 23% glycerol, and 
0.2M DTT in 0.1% w/v bromophenol blue) and heated at 100°C for 5 min. Proteins were 
then loaded onto an SDS-PAGE gel using 4|ng of protein per track. The SDS-PAGE gel 
consisted of a separating gel (15% w/v acrylamide/bis-acrylamide, 0.37M Tris-Cl, 
pH8 .8 , 0.1% SDS, set by addition of 0.3% TEMED, 0.03% ammonium persulphate) 
with a 3% stacking gel (3% w/v acrylamide/bis-acrylamide, O.IM Tris-Cl pH 6 .8 , 0.1% 
SDS , plus 0.1 % lEMED and 0.05% ammonium persulphate). Electrophoresis was 
carried out at 20 mA for 1 hour using a Mighty Small II vertical slab gel unit (Hoefer 
Scientific Instruments). Low molecular mass markers obtained from Pharmacia (14,400- 
97,000 daltons) or prestained high molecular mass markers (14,400-200,000 daltons) 
from Gibco BRL w ere used. After electrophoresis (lie gel w as stailicd witll 0.1 % w/v 
Coomassie Brilliant Blue R-250 (Sigma) in methanol : water : ethanoic acid (5:5:1) and 
then destained with methanol:water:ethanoic acid (1:17:2).
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2.13 Immunoblotting
After SDS-PAGE, proteins were electrophoretically transferred to nitrocellulose paper 
(NCP, Schleicher & Schuell, 0.45 pm pore size) to allow immunodetection of the 
proteins which could be recognised by the Mabs. The proteins were transferred in a 
Hoefer TE Series Transphor apparatus at 120 mA, for 1 h at 4°C, using 25 mM Tris- 
HCl, 150 mM glycine, 20% y/v methanol, by the method of Towbin et aL (1979).
After transfer the blots were blocked by incubation with a solution of 3% non-fat milk 
powder in PBS for 30'
min at room temperature, and were then washed three times (3X) in PBS, 
containing 0.05% v/v Tween-20 (Sigma) (PBS/T). Blots were then incubated with a 
solution of Mab (5pg/ml) in PBS/T for 1 hour at room temperature. Blots were then 
washed 3X, and incubated in a solution of affinity purified goat anti-mouse polyvalent 
immunoglobulin conjugated to peroxidase, at a 1:1000 dilution (Sigma), for 1 hour at 
room temperature. Blots were washed again in PBS (3X) and then antibody binding was 
detected by incubation in a solution consisting of 10 ml of 3 mg /ml 4-chldro-1 -napthol 
(Sigma) in methanol, mixed with 50 ml of 50 mM Tris-HCl pH 7.5, and 30 pi of 30% 
H2O2 . The reaction was stopped by washing three times in H2O (Blackman et al., 1991).
2.14 Immunoprécipitation (IPP)
This technique allows the identification of small amounts of a single protein in a 
complex mixture, by interaction with antibodies. The biggest advantage of using Mabs
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for this method is the specificity of their interaction to allow the precipitation of a single 
antigen from a radiolabelled mixture of proteins, which can be analysed by 
polyacrylamide gel electrophoresis and fluorography.
Trophozoites, schizonts and merozoites were obtained from P. yoelii infected mouse 
blood, after passage through a CF-11 column to remove leukocytes (Richards & 
Williams 1973). The trophozoites and schizonts were isolated by centrifugation through 
a percoll gradient (the trophozoite and schizont layer was at between 60-70 % percoU). 
The parasites were washed twice in cysteine and methionine free RPMI 1640 medium, 
and then incubated for 1 hour at a 1 0 % haematocrit in cysteine and methionine free 
RPMI medium, containing 2 MBq ml’* TRAhP^SLABEL (70% P^S] L-methionine, 15% 
P^S] L-cysteine, ICN). The supernatant was first harvested by centrifugation at 500 g 
for 5  min, then the pellet containing the parasitised erythrocytes was washed and 
solubilised in lysis buffer (50 mM Tris-HCl pH 8.0 containing 5 mM EDTA, 5 mM 
EGTA and 1 % NP40) (Holder and Freeman, 1981).
Five microgrammes of each Mab were added to aliquots of the parasite lysate and 
incubated for Ih in order to form an immune complex. Then lOpg of rabbit anti-mouse 
IgG (Serotec) were added, and finally protein A sepharose beads were added and 
incubated for 1 hour at 4°C, The beads were washed well with 50mM Tris-HCl pH 8.0, 
5mM EDTA and 0.5% NP40 and the purified immune-complexes were analysed by 
SDS-polyacrylamide gel electrophoresis on 10 and 12% polyacrylamide gels. Gels were 
stained with Coomassie blue, destained, soaked for 15 minutes in Amplify (Amcrsham) 
and then vacuum dried on to paper at 80°C and exposed to X-ray film (X-OMAT-AR 
from Kodak) at -70°C to identify radiolabelled proteins by fluorography.
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Immunoprécipitation was used to evaluate the Mabs. A mouse polyclonal serum against 
recombinant MSP-119 (Ling et al., 1994) and Mab 25.1 (Holder & Freeman, 1981) were 
used as positive control antibodies and normal mouse serum was used as a negative 
control.
2.15 Preparation of parasite extracts for western blotting
A group of 10 female BALB/c mice at least 8  weeks-old, were infected by 
intrapeiitoneal injection of 10  ^ P. yoelii YM parasitised red blood cells. When the 
parasitaemia was about 30% the mice were sacrificed and parasites were isolated by 
centrifugation through a 60-80% percoll gradient ( Richards & WÎUiams, 1973). The 
parasites were solubilised in lysis buffer at 4°C for 1 h and then the solution was 
centrifuged at 500 g for 30 minutes. The soluble parasite extract was used as antigen in 
Western blotting (Section 2. 13).
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CHAPTER 3: MONOCLONAL ANTIBODY PRODUCTION AND
CHARACTERISATION
3.1 Introduction
The asexual development of the malaria parasite in the blood of the vertebrate host is 
characterised by cyclic growth and multiplication within the erythrocyte. MSP-1 is 
synthesised as a large protein precursor during the later stage of parasite development in 
the erythrocyte known as schizogony, and is proteolytically cleaved into a complex of 
smaller polypeptide fragments found on the merozoite surface. The C-terminal 19kDa 
fragment of MSP-1 is the only fragment retained on the surface and carried into the 
erythrocyte at invasion. MSP-1 is one the most prominent candidates for a vaccine 
against the asexual blood stage; based on experiments conducted using the human 
malaria parasite P. falciparum and other species such as the simian parasite P. knowlesi 
(David et al., 1984) and the rodent parasite P. clmbaudi (Lew et al., 1989; O’Dea et al., 
1995). The C-terminal fragment is in particular the focus of vaccine design (Holder, 
1988; Cooper, 1993; Daly & Long, 1995) since it is the most logical target for blocking 
erythrocyte invasion (Locher et al., 1996). Epitopes within the C-termirml region that 
are recognised by Mabs may be important in the induction of a protective humoral 
response during malaria infection.
Polyclonal and monoclonal antibodies specific for the 42 and 19 kDa fragments of MSP- 
1 inhibit pamsite growth in vitro (Blackman, et al., 1991; Pirson & Perkins, 1985; 
Chang, et al., 1992; Chappel & Holder, 1993), but only a limited number of studies have 
investigated whether or not Mabs can provide passive immunity in vivo (Majarian et al.
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1984). Recently, the C-terminal portion of P. yoelii MSP-1 (the 19kDa fragment) was 
produced in a bacteria expression system as a fusion protein with glutathione S- 
transferase. Immunisation with this fragment (containing both EGF-like modules) 
protected mice against lethal parasite infection (Daly & Long, 1993; Ling et al., 1994). 
There are 10 highly conserved cysteine residues within the two EGF-like motifs of MSP- 
l i9 (Daly et al., 1992) which are predicted to form 5 disulphide bonds that stabilise the 
formation of a complex three-dimensional structure. It has been shown that protein that 
is unfolded by reduction and alkylation is unable to induce protective immunity (Ling et 
al., 1994). Consequently a recombinant MSP-119, which is suitable for vaccination of 
mice, has to be correctly folded.
Study of the immunological response to immunisation with the C-terminal region of 
MSP-1 and a detailed characterisation of the epitopes within this region will provide a 
greater understanding of the protective immune response to this antigen and of its 
function. In this study Mabs were produced and characterised to define potential 
protective epitopes.
3 2  Purification of various recombinant MSP-1 proteins for analysis of the Mabs
In order to characterise the monoclonal antibodies for reactivity with the 19kDa 
fragment of MSP-1, three recombinant proteins were produced and used in western 
blotting experiments. The first, second and combined EGF-like motifs of MSP-1 were 
expressed in E. coli as fusion proteins with glutathione S-transferase (GST-MSPIEGFI, 
GST-MSP1EGF2 and GST-MSPI19, respectively). These fusion proteins were purified 
from bacterial lysates by glutathione-affinity chromatography. Hie eluted fractions were
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monitored by SDS-PAGE onl5% polyacrylamide gels and those containing the highest 
concentration of each protein were collected, pooled and dialysed against PBS . In this 
way the three different proteins were purified (see Figures 3.2, 3.3 & 3.4), together with 
the GST carrier (Figure 3.5). Figure 3.6 shows an analysis on a 12.5% SDS-PAGE gel 
of the purified recombinant proteins after glutathione-affinity chromatography.
Recombinant MSP-119, cleaved from the GST carrier with Factor Xa, was also 
produced. As shown in Figure 3.7, the MSP-1 sequence was released in soluble form 
after cleavage by digestion with blood coagulation Factor Xa.
33  Selection of hybridomas secreting MSP-l-specific monoclonal antibodies
In an initial study, five BALB/c mice were immunised with MSP-119 recombinant protein 
at two weekly intervals. A total of five i.p. injections (0.13mg/ml of antigen for each 
immunisation) were given. For primary immunisation, Freund’s complete adjuvant 
(FCA) was used to emulsify the antigen and subsequent immunisation was conducted 
using Freund’s incomplete adjuvant (FLA). Prior to removal of the spleens for hybridoma 
production the antibody titres of sera obtained from tail vein bleeds of mice were 
determined by IFA. Mice were boosted until the antibody titres of the sera were at least 
1:3200 (Harlow & Lane, 1988) (see Chapter 2). The spleens of these BALB/c mice that 
were immunised with the recombinant protein MSP-119 were removed and the cells fused 
with SP2/0-Agl4 myeloma cells. MSP-l-specific Mabs were initially identified by 
screening hybridoma supernatants using an ELISA with 1 pg/ml affinity-purified MSP- 
119. Two hybridoma cell lines that produced antibodies reactive with the recombinant 
MSP-119 were obtained and named BIO and G3.
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A second set of hybridomas was made using the spleens of mice which had survived 
infection with P. yoelii YM. Mice from a passive immunisation experiment in which 
the animals received either Mab BIO or G3 and then were challenged with parasitised 
erythrocytes, were subsequently inoculated with 5 x 10* parasitised red blood cells on 
three occasions and the spleens harvested 7 days later. Figure 3.1 shows the 
immunisation protocol. This additional fusion experiment resulted in the production of 
several hybridomas, including P2-F5, P6 -B6 , P3-D3, and P5-D9. Positive antibody 
reactions obtained by using ELISA were checked for aU the monoclonal antibodies by 
using IFA. One hundred and four of three thousand hybrid cell wells produced antibodies 
reactive with recombinant MSP-119 in ELISA and of these a small number of hybridoma 
supernatants gave a positive result by IFA. Each one of the Mabs showed a characteristic 
“bunch of grapes” staining pattern with the P. yoelii infected erythrocytes, 
corresponding to merozoites in schizont infected red blood cells.
I have produced a panel of twelve hybridoma cell lines that secrete antibody specific for 
P. yoelii MSP-1. Hybridomas BIO and G3 were produced after immunisation with the 
recombinant GST-MSPI19. The other hybridomas were produced from the spleens of 
mice which survived the parasite infection after passive immunisation with either Mab 
BIO or G3. Hie antibodies from only six hybridoma cell lines (BIO, G3, P2-F5, P6 -B6 , 
P3-D3, P5-D9) have been characterised in detail by a number of different techniques, 
and were chosen based on initial passive immunisation studies which indicated that these 
antibodies were fuUy or partially protective against a blood stage parasite challenge 
(Chapter 4).
42
3.4 Purification of Mabs by Protein G chromatography
The individual Mabs were purified before being characterised in detail, and for this 
purpose affinity chromatography on Protein G-sepharose was used. Protein G is an 
immunoglobulin G (IgG)-binding bacterial cell wall protein isolated from group G 
streptococci. The avidity of protein G for various monoclonal and polyclonal antibodies 
of the IgG class is greater than that of protein A. Protein G binds all monoclonal IgG 
from mouse: IgGl, IgG2a, IgG2b and IgG3, and rat: IgG2a, IgG2b, and IgG2c. Li 
addition, it has been shown to bind polyclonal IgG from a variety of mammals, including 
human, cow, rabbit, goat, rat, and mouse antibodies, whereas chicken IgG does not bind. 
(Akerstrom et al. 1985).
To produce large amounts of the Mabs, the hybridomas were grown in vitro and the 
secreted antibody purified from the culture medium. The medium from the cultured cells 
was harvested and concentrated by a factor of approximately 1 0 , before being passed 
through a Protein G-sepharose 4 Fast Flow column to purify the individual antibodies. 
The bound antibody was eluted from the column, dialysed, and analysed by SDS-PAGE 
for purity. Figure 3.8 shows an analysis of the different purified Mabs, using SDS- 
PAGE under reducing conditions (15% polyacrylamide) and detecting the proteins with 
coomassie blue. For each sample the component heavy (~50kDa) and light (~25kDa) 
chains of the IgG molecules are visible.
SDS-PAGE analysis was also used to discriminate between two Mabs of similar 
properties. Li mouse the light chain exists in two distinct forms called kappa and
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lambda. The different light chain types may combine with any of the heavy chain types, 
but in any one molecule both light chains are of the same type (Roitt et al. 1993). Two 
antibodies, P6 -B6  and P2-F5 had similar biological activity, providing protection against 
challenge infection (see Chapter 4) and were of the same subclass (IgG3, see below), 
however they could be distinguished from one another by the mobility of the respective 
light chain in SDS-PAGE electrophoresis (see Figure 3.9). This result indicates that 
these Mabs are the products of two distinct different hybridoma clones.
3 3  Determination of Mab subclass
The IgG subclasses of the purified antibodies were determined by immuno-diffusion in 
agar using rabbit antirmouse Igs, and by capture ELISA, using the methods described in 
Chapter 2. The results are given in Table 3.1 which shows the determination of the 
subclass of the 12 Mabs which were analysed. The cloned hybridoma cells produced 
IgG from each of the subclasses. The subclass of each antibody will be discussed in the 
next chapter in the context of the results from the passive immunisation studies.
3 .6  Indirect Immunofluorescence assay identifies two antibody specificities
The ability of the purified Mabs to react with the parasite was confirmed using the IFA 
test. Hybridoma cell lines had been selected by two assays to analyse the specificity of 
their secreted Ig: ELISA with the recombinant MSP-119, and immunofluorescence on 
methanol-fixed smears of parasitised erythrocytes. The Mabs produced by the cloned cell 
lines were again tested by IFA (Pirson & Perkins, 1985).
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In the re-analysis of six Mabs, two different patterns of reactivity were noted. Mabs 
BIO, G3, P2-F5, P6 -B6  stained schizont, merozoite and ring forms (see Rgures 3.10, 
3.11, 3.12, and 3.13). However, the Mabs P3-D3 and P6-B4 produced a slightly 
different pattern, they stained around the schizont and merozoite surface, but did not 
react with ring forms (see Figures 3.14 and 3.15 respectively). In P. falciparum the C- 
terminal 19kDa fragment of MSP-1 is the only part of the molecule that remains on the 
merozoite during invasion and can be detected in ring stage parasites (Blackman et al., 
1990). By analogy, it is likely that the first group of four antibodies is directed against 
the equivalent part of P. yoelii MSP-1, whereas the second group of two antibodies is 
against another part of the molecule (see below for a more detailed analysis of the 
epitopes for these antibodies). In view of these findings, it is difficult to explain why 
these two hybridomas were selected, since the initial selection was for those that 
secreted antibody that reacted with MSP-119 in ELISA.
3.7 Immunoprécipitation ^ P )  of MSP-1 from extracts of parasites
Detergent extracts of merozoites and schizonts, radiolabeUed with ^S- 
methionine/cysteine, were mixed with individual Mabs, as well as normal mouse serum 
and an anti-serum to recombinant P. yoelii MSP-119 (Ling et al., 1994) as negative and 
positive controls, respectively. The immune complexes formed were precipitated and 
then analysed by SDS-PAGE (12.5% polyacrylamide gel) under reducing conditions. In 
this immunoprécipitation all Mabs recognised a major band of 230kDa in lysates from 
schizonts (Figs. 3.16 and 3.17), which was also recognised by Mab 25.1 (Holder & 
Freeman, 1981) and a polyclonal serum specific for MSP-119 which were used as 
positive controls. MSP-1 has been shown to be cleaved to a series of lower molecular
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mass polypeptides and therefore the other polypeptides in these tracks may represent 
some of these fragments.
3.8 Use of immunoblotting with recombinant proteins and parasite extracts to 
define the antibody binding sites
To confirm the reactivity of the Mabs with MSP-1, and identify more precisely the 
epitopes they recognise, the ability of the antibodies to bind to recombinant proteins 
expressed from parts of the MSP-1 gene was investigated by western blotting. 
Recombinant proteins (GST-MSPlw, GST-MSPIEGFI, GST-MSP1EGF2 and GST- 
MSP-I33 ), or parasitised erythrocytes extracted with 50mM Tris-HCl pH 8.2, 5mM 
EDTA, 0.5% w/v NP-40, were denatured in SDS-PAGE sample buffer, resolved by 
PAGE on 12.5% polyacrylamide gels and then electrophoretically transferred to 
nitrocellulose. The purification of the recombinant proteins based on MSP-119 was 
described in Section 3.2 (see Figure 3.6).The results of these experiments are shown in 
Figures 3.18, 3.19 and 3.20.
Mabs BIO, G3, P2-F5 and P6 -B6  all bound to GST-MSPI19 , indicating that they 
recognise epitopes in the C-terminal cysteine-rich region of MSP-1. None of the Mabs 
bound to GST-MSP1EGF2, but both P2-F5 and P6 -B6  bound to GST-MSPIEGFI. 
This reactivity was abolished if the recombinant proteins were reduced and alkylated 
with iodoacetic acid before SDS-PAGE, a treatment that prevents refolding of the 
proteins after electrophoresis and destroys epitopes that require disulphide bonds for 
their maintenance (Burghaus & Holder, 1994). These results suggest that BIO and G3 
recognise epitopes that require both EGF-like motifs to be present in the recombinant
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protein. The epitopes recognised are formed when both motifs are expressed together 
and these epitopes could contain amino acids from both motifs or the precise sequence 
configuration required for antibody binding in one motif is constrained by the presence of 
the other one. This observation also has been made with Mabs to P. falciparum MSP- 
1, such as Mabs 12.10 and 111.2 (Chappel & Holder, 1993; Burghaus & Holder, 
1994).
Mabs P6-B4 and P3-D3 did not bind to GST-MSPI19, GST-MSPIEGFI or GST- 
MSP1EGF2, although both Mabs recognised MSP-1 by immunoprécipitation (Fig. 
3.16). These are the antibodies that did not react with the ring stage parasites by 
immunofluorescence (Section 3.4). The epitope of Mab P6-B4 was mapped to MSP-1 
sequence immediately N-terminal to MSP-119, corresponding to the 33kDa fragment of 
P. falciparum MSP-1 that is produced as a result of secondary processing (Blackman 
et al., 1993). A new recombinant protein corresponding to a large part of the predicted 
P. yoelii MSP-133 fused to GST was used to map the epitope of Mab P6-B4 (Rg 3.21). 
The recombinant protein contains the amino acid sequence corresponding to residues 
1394 to 1633 in the P. yoelii MSPl sequence (Lewis, 1989). The other Mabs did not 
bind to the recombinant GST-MSP-I33 protein in Western blotting (data not shown).
Western blotting was also performed with extracts of parasites to try to identify 
fragments of MSP-1 that reacted with Mab P3-D3. This Mab appeared to recognise a 
42kDa fragment of MSP-1 in merozoite extracts (Fig 3.22). The same polypeptide was 
recognised by the other Mabs. Since Mab P3-D3 seems to recognise the C-terminal 
42kDa fragment of MSP-1 by western blotting, but not GST-MSPI19 or GST-MSPI33
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that comprise this fragment, it is possible that the epitope recognised by this antibody 
requires the larger conformational structure for formation.
3. 9 Evaluation of the fine specificity of Mab binding to MSP-I19 by competition 
ELISA
Four monoclonal antibodies appeared to bind to the C-terminal MSP-119 sequence by 
western blotting (Section 3.6), therefore the fine specificity of this binding was analysed 
in more detail by competition ELISA (Table 3.2). In this assay the antigen (recombinant 
MSP-119) was bound to a microtitre plate and the ability of an unlabelled antibody to 
block the binding of a labelled antibody was determined by titration.
The purified Mabs were biotinylated and the titre of each was m easured by serial 
dilution to establish the proper working dilution at which to use the antibody in the 
competition ELISA. Table 3.2 shows the titres of biotinylated Mabs and the working 
dilution used for each Mab in the competition ELISA. As expected from the western 
blotting studies, BIO, G3, P2-F5 and P6 -B6  reacted with the recombinant MSP-119, 
whereas P3-D3 did not. Nevertheless this antibody was included in the experiments as a 
control preparation. To analyse the competitive ELISA results, the minimum significant 
Absorbance value for each antibody was established from the Mean + 2 Standard 
Deviations of the Absorbance of the Mab inhibited by itself. Data from the competition 
ELISA between BIO and G3, and P6 -B6  and F2-F5 were analysed using the Kruskal-
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Wallis statistical test (Figures 3.23, 3.24, 3.25 and 3.26) with a values of P = 0.04, 0.03, 
0.04 and 0.01 for Mabs P2-F5, P6 -B6 , BIO and G3 respectively.
Figures 3.23 and 3.24 show the mean Absorbance values obtained in the competition 
ELISA experiments, using biotinylated P2-F5 and P6 -B6 . The results shown in Figure 
3.23 indicate that the mean Absorbance value with the biotinylated Mab P2-F5 was 
lower when the Mab P6 -B6  was used as the primary antibody when compared with the 
control (non-biotinylated P2-F5 vs. biotinylated P2-F5). This result suggests that P6 -B6  
interferes with the binding of P2-F5. This effect was not observed when Mabs P3-D3, 
BIO, G3 and P6-B4 were used as primary antibodies as shown in Figure 3.23, i.e. in 
these cases the mean Absorbance values for the biotinylated Mab P2-F5 were greater 
than in the control. These differences were statistically significant (P=0.04) by the 
Kruskal-Wallis test Figure 3.24 shows a similar experiment using biotinylated P6 -B6 . In 
this case the mean Absorbance value for the biotinylated antibody was greater than the 
control (non-biotinylated P6 -B6  vs. biotinylated P6 -B6 ) when P2-F5 was used as the 
primary antibody, suggesting that the binding of P2-F5 did not affect the binding of P6 - 
B6 . Similar results were observed with aU the other non-labelled Mabs employed 
(P=0.03, Kruskal-Wallis test). Hiese data indicate that the epitopes recognised by these 
Mabs are different from the one recognised by P6 -B6 . Similar analyses were carried out 
for each of the Mabs included in this study. Mab G3 competed with BIO, although BIO 
was not able to compete effectively with G3 (Figures 3.25 and 3.26).
The results of the competition ELISA can be summarised as follows and are presented in 
Table 3.3. Mab P6 -B6  competed with P2-F5, but not with any of the other antibodies, 
although P2-F5 was not able to compete effectively with P6 -B6  or with any of the other
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antibodies. Mab G3 competed for binding with Mab BIO but not with any of the other 
antibodies. Mab BIO did not compete with G3 or with any of the other antibodies. 
Apparently, therefore, each pair of Mabs, G3 and BIO and P6 -B6  and P2-F5 do not 
recognise identical epitopes, because there is competition in only one direction, i.e. when 
the Mabs G3 or P6 -B6  are initially bound, but not in the opposite case when BIO or P2- 
F5 were used as the primary antibody. These results suggest that the epitopes recognised 
by the Mabs G3 and P6 -B6  are adjacent to the ones recognised by Mabs BIO and P2-F5, 
respectively. It is feasible that the initial binding of G3 and P6 -B6  cause a steric effect or 
the induction of a conformational change in the antigen, affecting the binding of Mabs 
BIO and P2-F5. Li other words, the binding of the second Mab (BIO or P2-F5) may 
depend on the arrangement of the first Mab (G3 or P6 -B6 ) or the precise configuration 
of the MSP-119 molecule. As expected from the western blot data, P3-D3 and P6-B4 
did not bind to MSP-119 . These competition ELISA results are consistent with the 
results of the western blotting studies, suggesting that the epitopes for BIO and G3 are 
very close to one another and different from the epitopes for P6 -B6  and P2-F5, which 
also appear to be close to each other.
3.10 Discussion.
Li the present investigation, I have produced a number of hybridomas and characterised 
their antibody products. Li initial studies the mice were first immunised with a 
recombinant MSP-119 protein, based on the observation that mice immunised with the 
recombinant P. yoelii MSP-119 could elicit a protective antibody response (Daly & Long, 
1993; Ling, et al., 1994). However, a low frequency of hybridomas that produced MSP- 
l-specific Mabs which were biologically active (see Chapter 4), was obtained.
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Therefore, to try to increase the chance of isolating hybridomas that secreted biologically 
active antibody, a different immunisation regime was employed. Mice that had been 
passively immunised with Mab BIO and G3 and had survived the challenge infection, 
were inoculated wiüi üve parasitised erythrocytes to boost the immune response and 
then the spleens were removed and used for hybridoma production.
In the initial assay for hybridomas of interest a two stage screen consisting of an ELISA 
with MSP-119 followed by IFA with parasitised erythrocytes was developed. The 
ELISA was used as the first stage of the screen because of the ease of this format for 
screening large numbers of cell supernatants for the presence of specific antibody. 
However, it was found that a large number of false positive results were obtained, and 
these supernatants did not contain antibody that reacted with the parasite (as assessed by 
IFA). This was possibly due to contaminants (for example of bacterial cell origin) in the 
MSP-119 material that was used for the immunisation and the ELISA. However the 
proteins appeared to be substantially pure as assessed by SDS-PAGE. Another 
explanation could be that the recombinant protein (or a fraction of it) folds incorrectly 
and therefore presents epitopes that are not present in the native protein. This second 
explanation is probably the most Hkely, but no attempt was made to fractionate either 
GST-MSPI19 or the recombinant MSP-119, for example by HPLC, to test whether or 
not there were different conformational forms of the protein present in the preparations. 
IFA was used for the second stage of the screen. This technique has the advantage that 
it detects native parasite antigens, but it is not convenient for screening large numbers of 
hybridoma culture supernatants, and although the pattern of fluorescence gives some 
clue to the location of the antigen and therefore its possible identity, it does not allow the 
identification of specific parasite proteins. A combination of the two assays was
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expected to provide a good screen to identify monoclonal antibodies of the desired 
specificity. Despite the use of this screen, two hybridomas were identified that produced 
MSP-l-specific antibodies that did not bind directly to MSP-119.
The results of the IFA and immunoprécipitation studies with the purified Mabs indicate 
that they recognise epitopes on the 230kDa P. yoelii MSP-1 precursor protein (Holder 
& Freeman 1984). Previous studies using immunoprécipitation of metabolically labelled 
polypeptides and western blotting showed that the precursor protein can be processed 
into a series of smaller fragments (Holder & Freeman, 1981; 1984). Two distinct 
patterns of reactivity were seen in the IFA, despite the fact that the antibodies were all 
against MSP-119: some antibodies reacted with schizonts and merozoites, but others 
reacted with early ring stages, in addition to the late stage parasites. This difference can 
be explained by the processing of MSP-1 that occurs at or just before invasion. Mabs 
which recognise MSP-119, the C-terminus of MSP-1, will react with ring stages because 
this part of MSP-1 is retained on the parasite surface during erythrocyte invasion, 
whereas Mabs that bind to epitopes elsewhere in the molecule would not react with ring 
stages because the rest of the molecule is shed from the parasite surface at the time of 
invasion.
Data obtained from the Western blotting experiments indicated that the epitopes 
recognised by some of the Mabs were expressed by the recombinant proteins. The 
epitopes for four of the antibodies were located in the C-terminal cysteine rich EGF-like 
motifs of MSP-1. After electrophoresis of the proteins that were untreated or had, been 
reduced with dithiothreitol, they reacted with the antibodies. However, if the reduction 
was followed by alkylation to modify any free -SH groups and prevent the reformation
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of disulphide bonds occurring after the transfer of the proteins to nitro-cellulose, then the 
binding of the antibodies was abolished. It is also possible that the presence of the alkyl 
groups (-CH2COOH) on the cysteine side chains could interfere sterically with antibody 
binding. However, MSP-1,g appears to contain the epitopes that are recognised by Mabs 
BIO, G3, P2-F5 and P6 -B6 . Furthermore, the epitopes recognised by P2-F5 and P6 -B6  
were found to be located in the first EGF-like motif, whereas G3 and BIO required the 
presence of both motifs for reactivity. The epitopes appear to require the presence of 
disulphide bonds for their maintenance; in the same way, Mab 302 obtained by other 
investigators (Majarian et a/., 1984) is also dependent on the presence of disulphide 
bridges at the C-terminus of P. yoelii MSP-1. The structure of extracellular proteins is 
often stabilised by the presence of disulphide bonds to maintain their conformational 
form, which is frequently necessary for efficient protein-protein interactions and 
required for maintenance of biological activity. Li this respect the recombinant proteins 
show the same properties as the natural molecules (Bums et al., 1989; Burghaus & 
Holder, 1994). Probably there is a strong selective pressure to maintain the structure and 
implied function in this region of the MSP-1 molecule because the cysteine-rich region of 
EGF-like motifs and the proteolytic cleavage sites are conserved in MSP-1 in different 
Plasmodium species and strains (Bums et al., 1989; Daly et al., 1992; Kang & Long, 
1995; Tolle et al., 1995). The available Mabs may also be used to define the epitopes 
most important in the immune response . This question is addressed in the next chapter, 
describing passive immunisation trials with these Mabs.
Two Mabs, P6-B4 and P3-D3, did not react with the recombinant proteins 
corresponding to MSP-1,9 or the individual EGF-like motifs. Another recombinant 
protein corresponding to MSP-133 was used to locate the epitope recognised by Mab P6 -
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B4 to this fragment. Mab P3-D3 (which was protective in passive immunisation studies, 
see next chapter) did not recognise any recombinant proteins by Western blotting. 
However it did recognise a band of 42kDa in a western blot using a parasite extract, and 
this band was also recognised by the other MSP-l-specific antibodies that reacted with 
the C-terminus. Therefore, it is possible to deduce that the epitope recognised by P3-D3 
is on the 42 kDa C-terminal fragment of MSP-1. Hie fact that this antibody did not react 
with the recombinant polypeptides suggests that the full length 42kDa polypeptide is 
required to form the epitope. However, because the recombinant GST-MSP-I33 is not 
quite full length it is possible that the epitope for P3-D3 is at one end of the linear 
polypeptide sequence. If the full length polypeptide is required, this may be because 
amino acids from both the 33kDa and 19kDa regions contribute to the antibody 
recognition site, or the conformation of the polypeptide is changed as a result of the 
secondary processing. Peptide bond cleavage, for example that which occurs in primary 
and secondary processing of MSP-1, can both create and destroy epitopes. There is the 
intriguing possibility that the P3-D3 epitope is formed by the secondary processing site. 
Since there is good evidence in P. falciparum that inhibition of secondary processing can 
be mediated by antibodies binding to MSP-119 and that this correlates with inhibition of 
invasion (Blackman et al., 1994), the fine specificity of P3-D3 is of great interest
In this study the fine specificity of the antibodies that bind to epitopes on MSP-119 was 
investigated by using a competition ELISA. This test is based on the inhibition of binding 
of one Mab by another that binds to an epitope that is either identical, overlapping or 
adjacent. My results with the competition ELISA confirmed the results of the western 
blot study showing that there are two groups: G3/B10 and P6-B6/P2-F5, and suggest 
that there may be a steric blocking between Mabs G3/B10 and P6-B6/P2-F5 by the
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recognition of adjacent epitopes. It is also possible that if the affinity of the antibodies 
within the two groups are widely different, and then this type of one-way competition 
could occur, in which one high affinity antibody displaces a bound lower affinity 
antibody.
The summary of the proposed interaction between Mabs and MSP-1 is shown in Rgure 
3.27. This displays MSP-1 and the fragments obtained after proteolytic cleavage (based 
on the model developed for P. falciparum [Blackman et al., 1990; David et al., 1984; 
O’Dea et al., 1995; Chappel & Holder, 1993; Farley & Long, 1995]) and the suggested 
location of the epitopes for the antibodies. In total, 6  Mabs were assessed in detail and 
they bound to different sites at the C-terminus of MSP-1. Mabs BIO and G3 recognise 
the double EGF-like motifs of MSP-119. Mabs P2-F5 and P6 -B6  recognise an epitope 
within the first EGF-like motif. Mab P6-B4 recognises an epitope in MSP-133 at the N- 
terminus of MSP-142 and P3-D3 appears to require the complete 42kDa polypeptide to 
bind. In the next chapter I describe the results of passive immunisation with these 
antibodies.
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Table 3.1.
Subclass analysis of the monoclonal antibodies.
Mab Subclass
P4-D10 IgGl
P1-C5 IgGl
P8-D1 IgGl
P1-A9 IgG2a
P8-D4 XgG2b
P5-D9 IgG2b
P6-B4 IgGl
P3-D3 IgG2a
P2-F5 IgG3
P2-F5/P IgG3
P2-F2/S IgG3
P6 -B6 IgG3
BIO IgG2b
G3 IgGl
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Table 3.2.
Titres for biotiriylated Mab binding to MSP-119.
Biotinylated Mab Titre Working dilution
BIO 1:25,600 1 :1 0 ,0 0 0
G3 1:25,600 1 :1 0 ,0 0 0
P2-F5 1:25,600 1 :1 0 ,0 0 0
P6 -B6 1:25,600 1 :1 0 ,0 0 0
P3-D3 1 :2 0 0 1 :1 0 0
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Table 33.
Comparison of the different Mabs by competition ELISA.
Labelled Mab
non-Labelled
Mab BIO G3 P2-F5 P6-B6 P3-D3
BIO 0 - - - -
G3 + 0 - - -
P2-F5 - - 0 - -
P6-B6 - - + 0 -
P3-D3 - - - - 0
P6-B4 - - - - -
PBS - - - - -
0: The Absorbance value in the competition ELISA corresponds to the value of the
non-biotinylated Mab competing with itself.
+: Inhibition of binding of the biotinylated Mab to MSP-119 by the non-labelled
Mab.
No inhibition of binding of the biotinylated Mab to MSP-119 by the non-labelled 
Mab.
These results were completely reproducible in three separate experiments.
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Figure 3.1.
The immunisation protocol used to generate the second set of hybridomas. Mice that 
had been protected against challenge infection with the lethal parasite P. yoelii YM, by 
passive immunisation with either Mab BIO or G3, were inoculated with parasites on 
three occasions prior to harvesting the spleens. On each occasion the mice received 5 x 
10* parasitised red blood cells containing P. yoelii YM.
2  weeks 1 week 1 week
day 0__________ dayl5___________ day 2 2 __________ day 29 FUSION.
inoculation boost boost
of parasites
59
Figure 3 2.
SDS-PAGR analysis of purified GST-MSPIEGFI recombinant fuson protein eluted 
with 8M urea from a glutathione-agarose column. Fractions containing the purified 35 
kDa protein (fractions 6 to 9) were pooled and dialysed against PBS. This protein 
contains the first EGF-like motif from MSP-1.
On this 15 % polyacrylamide gel, the standard molecular mass marker proteins indicated 
are: phosphorylase b (97 kDa), bovine serum albumin (66 kDa) , ovalbumin (47 kDa), 
carbonic anhydrase (30 kDa), and soybean trypsin inhibitor (20 kDa).
6 0
kDa 5 6 7 8 91011i- r .
9 7 -
Spencer 1 3/6/97 
N.I.M.R. A'11'7 74,1.
Figure 3.3.
SDS-PAGE analysis o f  purified GST-M SP1EGF2 recombinant fusion protein eluted 
with 8 M urea from a glutathione-agarose column. Fractions containing the purified 32  
kDa protein (fractions 6  to 8 ) were pooled and dialysed against PBS. This protein 
contains the second EGF-like motif from M SP-1. On this 15 % polyaciylamide gel, the 
marker proteins are as indicated in Figure 3.2.
6 1
kDa i  ^ .1 , 5  6  7  8  9 1 0  11
4 7  -  
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London. A'li'7 /.4,4.
Figure 3.4.
SDS-PAG E analysis o f purified G S T -M SP l,, recombinant fusion protein eluted with 
8 M urea from a glutathione-agarose column. Fractions containing the purified -4 0  kDa 
protein (fractions 3 to 6 ) were pooled and dialysed against PBS. This protein contains 
both the EGF-like motifs from M SP-1. On this 15 % polyacrylamide gel, the marker 
proteins are as indicated in Figure 3.2.
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Figure 3.5.
SDS-PAGE analysis o f purified GST recombinant protein eluted with 8 M urea from a 
glutathione-agarose column. Fractions containing the purified 26 kDa protein (fractions 
5 to 8 ) were pooled and dialysed against PBS. On this 15 % polyacrylamide gel, the 
marker proteins are as indicated in Figure 3.2.
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Figure 3.6.
Purified recombinant GST fusion proteins eluted from glutathione-agarose columns and 
resolved by SDS-PAG E on a 12.5 % polyacrylamide gel. In track 1 is the 26 kDa GST; 
track 2, the 32 kDa GST-M SPIEGFI fusion protein containing the first EGF-like motif 
o f  MSP-1; track 3, the 35kDa GST-MSP1EGF2 fusion protein containing the second  
EGF-like m otif o f MSP-1; and tracks 4 and 5, the 40 kDa G ST -M SPI 19 fusion protein 
containing both EGF-like motifs o f M SP-1. On the left half o f the figure the proteins 
were reduced with dithiothreitol prior to electrophoresis, and on the right half they were 
not reduced.
64
Reducing
condition
Non Reducing 
condition 
A
kDa
Spencer 6 29/11/95
N.Ï.M.R. .W7 /.44
Figure 3.7.
SDS-PAGE analysis on a 15% polyacrylamide gel o f recombinant M SP-1 19 protein after 
release from the G ST -M SPI19 fusion protein by digestion with Factor Xa. In Track A  
can be seen recombinant M SP-1 19 together with GST, and in track B can be seen the 
purified ~20kDa M SP-1 19 protein. The molecular mass markers are as in figure 3.2.
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Figure 3.8.
SDS-PAG E analysis (under reducing conditions) o f  Mabs purified by protein G affinity 
chromatography: Mab BIO (track 1), Mab P3-D3 (Track 2), Mab P2-F5 (track 3), Mab 
P6 -B 6  (track 4), Mab G3 (track 5), Mab P6-B4 (track 6 ), Mab P5-D9 (track 7) and Mab 
P1-C5 (track 8 ). The positions o f  standard molecular mass markers is indicated on the 
left. The IgG heavy and light chains at ~50kDa and ~25kDa, respectively, are indicated 
on the right.
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Figure 3.9.
The monoclonal antibodies P2-F5 and P6 -B 6  were compared by SDS-PAG E on 15 % 
polyacrylamide gels. The light chain (-2 5  kDa) and heavy chain ( -5 0  kDa) can be seen  
for both Mab P2-F5 (track 1) and Mab P6 -B 6  (track 2), and are indicated. Note  
difference in size o f  the light chain from the tw o Mabs. The positions o f standard 
molecular mass markers is indicated on the left.
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Figure 3.10.
Immunofluorescence pattern o f Mab BIO reacting with acetone-fixed P . yoelii  parasites 
in erythrocytes (x l250  magnification).
Figure 3.11.
Immunofluorescence pattern o f Mab G3 reacting with acetone-fixed P . yoelii parasites 
in erythrocytes (x l250  magnification).
6 8

Figure 3.12.
Iminunofluorescence pattern o f Mab P2-F5 reacting with acetone-fixed P. yoelii 
parasites in erythrocytes (x l2 5 0  magnification).
Figure 3.13.
Immunofluorescence pattenr o f Mab P 6 -B 6  reacting with acetone-fixed P. yoelii 
parasites in erythrocytes (x l250  magnification).
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Figure 3.14.
Lnmunofluorescence pattern o f Mab P3-D3 reacting with acetone-fixed P. yoelii 
parasites in erythrocytes (x l250  magnification).
Figure 3.15.
Immunofluorescence pattern o f  Mab P6-B4 reacting with acetone-fixed P. yoelii 
parasites in erythrocytes (x l250  magnification).
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Figure 3.16.
[^^S] methionine/cysteine-containing polypeptides iinmunoprecipitated from extracts o f  
parasitised erythrocytes by normal mouse serum (track 1), Mab 25.1 (track 2), Mab P5- 
D9 (track 3), Mab P6-B4 (track 4), Mab P3-D3 (track 5), Mab G3 (track 6), Mab BIO 
(track 7), Mab P6-B6 (track 8), and Mab P2-F5 (track 9). P. yoelii  YM  parasites were 
metabolically labelled with methionine/cysteine and solubilised in a buffer
containing the detergent NP-40 in the presence o f proteinase inhibitors. The 
immunoprecipitates were analysed by SDS-PAGE on a 12.5% polyacrylamide gel and 
labelled proteins were detected by fluorography. The mobility o f standard molecular 
mass markers is indicated, together with iinmunoprecipitated polypeptides marked by 
arrows.
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Figure 3.17.
Lnmunoprecipitation o f  [^^S] methionine/cysteme-labelled polypeptides from extracts o f  
P. yoelii  parasites: Mab P2-F5 (track 1), P 6 -B 6  (track 2), BIO (track 3), G3 (track 4), 
P3-D3 (track 5), P5-D9 (track 6 ), 25.1 (track 7), NM S (track 8 ) and polyclonal anti­
serum raised against recombinant M SP-1 19 (track 9). Other conditions were as described 
in the legend to Figure 3.16. The immunoprecipitates were analysed by SDS-PAGE  
(12.5% gel) and fluorography. The mobility o f molecular mass markers is indicated, 
together with immunoprecipitated polypeptides marked by arrows.
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Figure 3.18.
Mabs BIO and G3 recognise recombinant G ST -M SPI 19 under non-reducing conditions 
(track 1), but after the protein was reduced and alkylated (track 2), the Mabs no longer 
bound. The recombinant protein was separated by SDS-PAG E on a 12.5% 
polyactylamide gel and transferred to nitrocellulose paper, then the blots were probed 
with Mabs at a dilution 1: 200. Left hand panel: BIO; right hand panel:G3.
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Figure 3.19.
The Mabs P2-F5 and P 6 -B 6  recognise recombinant proteins containing the first and both 
the EGF-like motifs from M SP-11 9 . The proteins were separated by SDS-PAG E on a 
12.5 % polyacrylamide gel and the blots were probed with 1:100 dilution o f Mabs. Panel 
A  shows analysis o f the proteins that have been treated under reducing conditions and 
panel B an analysis o f the untreated proteins (non-reducing conditions). The proteins 
used were GST (track 1), G ST-M SPIEG FI (first motif fusion protein ) (track 2), GST- 
MSP1EGF2 (second motif fusion protein) (track 3) and G ST -M SP I 19 (track 4). The 
mobility o f molecular mass markers is indicated. Upper panels were probed with P2-F5 
and lower panels were probed with P 6 -B 6 .
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Figure 3.20.
Western blot o f using GST-M SPIEGFI (panel A) and G ST -M SPI 1 9 (panel B), probed 
with the Mabs P2-F5 and P 6 -B 6 . The antibodies recognised the recombinant proteins 
containing both the first and the double EGF-like motifs in non-reducing (track 3) and 
reducing conditions (track 2 ), but not when the proteins were reduced and alkylated with 
iodoacetic acid (track 1). The mobility o f molecular mass markers is indicated.
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Figure 3.21.
Western blot o f GST-MSPI33 and GST-MSPI19 recombinant proteins probed with Mab 
P6-B4 . The antibody recognised the ~50kDa MSP-133 fusion protein (track 1), but it 
did not recognise GST-MSPI19 (track 2) . The samples were reduced prior to  
electrophoresis. The mobility o f molecular mass markers is indicated.
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Figure 3.22.
Monoclonal antibodies react with polypeptides in an extract o f P. yoelii  parasites on 
western blots. The samples were reduced, subjected to electrophoresis and then blotted 
onto nitrocellulose. The blots were probed with: Mab BIO (lane 1 ); Mab G3 (lane 2); 
Mab P6-B4 (lane 3); Mab P 6 -B 6 (lane 4); Mab P2-F5 (lane 5); Mab P3-D3 (lane 6 ); Mab 
P5-D9 (lane 7); nonnal mouse serum (lane 8 ); Mab 25.1 (lane 9) and a polyclonal anti­
serum against M S P -I 19 (lane 10). The position o f the 42kDa polypeptide, and the 
mobility o f  molecular mass markers are indicated.
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Figures 3.23. and 3.24.
Tlie mean Absorbance values obtained in the competition ELISA experiments, using 
biotinylated P2-F5 (Fig. 3.23) and P6 -B 6  (Fig. 3.24) together with a series o f unlabelled 
Mabs, as indicated on the x-axis.
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Figure 3.23: Competition ELISA 
with biotinylated Mab P2-F5
2 . 0 - 1
1 .5 -
1 . 0 -
0 .5 -
0.0
P2-F5 P6-B6 P3-D3 B10 G3 P6-B4
Figure 3.24: Competition ELISA 
with biotinylated Mab P6-B6
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Figures 3.25. and 3.26.
Tlie mean Absorbance values obtained in the competition ELISA experiments, using 
biotinylated BIO (Fig. 3.25) and G3 (Fig. 3.26) together with a series o f unlabeUed 
Mabs, as indicated on the x-axis.
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Figure 3.25: Competition ELISA 
with biotinylated Mab B10
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Figure 3.26: Competition ELISA 
with biotinylated Mab G3
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Figure 3.27.
A  schematic showing the proposed structure o f P. yoelii  MSP-1 and the location o f the 
antibody binding sites. Based on the model developed for P. falciparum  MSP-1 the 
protein is present on the newly released merozoite surface as a complex o f  four 
polypeptides. A, B, and C correspond to the 83, 30 and 38kDa fragments o f P. 
falciparum  M SP-1, respectively . Tlie C-terminal 42 kDa fragment undergoes another 
proteolytic cleavage to give 2 fragments o f 33kDa (M SP-133) and 19 kDa (M SP-119). 
M SP-1 1 9 is represented as two EGF-like motifs (D‘ M. & 2"^  M .). All Mabs produced in 
this study bind epitopes on M SP-1 1 9 , except Mabs P6-B4 and P3-D 3, which recognised 
the 33kDa and 42 kDa polypeptides, respectively.
80
Precursor Protein of MSP-1
230 kDa
^  1 St cleavage
B 42 kDa
P3-D3
^  2nd cleavage
P6-B4
33 kDa 19 kDa
1st M 2nd
P2-F5
P6-B6
BIO
G3
Spencer 26/6/97 JS
CHAPTER 4; PASSIVE IMMUNIZATION OF M ICE AND CHALLENGE 
WITH P L A SM O D IU M  YOELII
4.1 Introduction
There are a number o f ways in which anti-plasmodial antibodies may affect and neutralise 
the parasite after they interact with the parasite or its specific proteins incorporated into 
the host erythrocyte cell membrane. Antibody could act by physically coating the 
parasite’s surface and therefore interfering with membrane function. Alternatively the 
antibody coating could change the adhesive characteristics o f the parasite or the 
parasitised erythrocytes, blocking receptor sites. Antibodies may also interfere with 
parasite release from the infected cell at the end o f schizogony (Kreier & Green, 1980), 
or prevent the nonnal growth and development o f the parasite by blocking invasion of  
host cells.
Immunity to the malaria parasite is mediated at least in part by the antibody response to 
the erythrocytic stages, since passive immunisation with immune serum or 
immunoglobulin provides some protection against rodent, simian, and human malaria 
(Boyle et ah, 1982). Mabs that inhibit parasite invasion o f host cells have been useful 
tools in the study o f malaria antigens, defining important epitopes. Monoclonal 
antibodies against the surface o f P. knowlesi merozoite recognise M SP-1, and inhibit 
reinvasion o f erythrocytes in vitro (Epstein et ah, 1981). A  Mab called 5B1 directed 
against P. falciparum  MSP-1 was used to characterise the protein and its role in 
erythrocyte invasion. This Mab recognised two polypeptides o f 200 and 50 kDa by IPP
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and it reduced merozoite invasion by approximately 45% (Pirson & Perkins 1985). 
Blackman et al. (1990) used a panel o f P. falciparum  M SP-1-specific Mabs and 
demonstrated that a complex o f polypeptides derived from the precursor is present on 
the parasite surface, and they demonstrated that antibodies to conserved epitopes on the 
19 kDa fragment o f MSP-1 can inhibit red blood cell invasion. Mabs together with 
recombinant proteins derived from MSP-1 have allowed the study o f the role of 
antibody-mediated mechanisms in M SP-1-specific immunity to P. yoelii infection 
(Majarian et al, 1984; Long et al. 1993; Ling et al., 1994).
Importantly, the role o f circulating antibody in malaria immunity has been studied by 
passive immunisation o f humans. In one study, with children living in The Gambia with 
severe clinical malaria, the therapeutic effect o f y-globulin prepared from the serum of  
apparently immune adults was demonstrated (Cohen et ah, 1961). Sabchareon and 
colleagues (1991) assessed the protective effect o f African IgG antibodies against P. 
falciparum  malaria by passive immunisation o f eight Thai patients. These patients were 
treated by i.v. inoculation o f IgG: six with a lOOmg/kg dose given over three days, one 
with a single 20 mg/kg dose, and one with a single 200 mg/kg dose. The IgG caused a 
decrease in asexual blood stage parasitaemia, while gametocytes were unaffected. After 
the disappearance o f the transferred antibodies, recrudescent parasites from three 
patients were found to be susceptible to the same IgG preparation, indicating that 
selection o f parasites able to escape the effect o f antibodies had not occurred. The 
authors concluded that the Afiican adult IgG pool exerted a consistent, but non­
sterilising effect on each strain tested ; this effect was stage-specific and probably 
species-specific.
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Another study was carried out by Aribot et al. (1996), in which they determined the 
pattern o f whole P. falciparum  antigen-specific immunoglobulin isotype distribution in 
the plasma from 145 Senegalese children and adults exposed to continuous and intense 
parasite transmission, high levels o f parasitaemia and the occurrence o f malaria attacks. 
The pattern o f anti-malarial immunoglobulin class (IgM and IgG) and IgG subclass 
(IgG l to IgG4) distribution was measured by ELISA using a crude blood-stage antigen 
o f  P. falciparum-m^ecXc^d red blood cells. Adults had higher levels o f specific antibodies 
than children, and IgM, IgG2, and IgG3 accounted for the highest difference. These 
differences in antibody levels were significant for IgG l to IgG4 between the lowest and 
highest transmission season. Only increased levels o f IgG3 were found to be associated 
with a significantly reduced risk o f malaria attack. These seroepidemiological data 
suggest that whereas the total parasite specific IgG is not indicative o f any given level of 
protection against malaria, the level o f IgG3 is associated with the relative susceptibility 
to clinical P. falciparum  malaria attack.
Much o f what has been learned about the role o f antibody in the control o f  malaria 
parasite infections has come from studies o f infected mice. However, these experimental 
models do not fully represent host-parasite associations that occur in nature and often 
fail to mitnic certain aspects o f human disease. Nevertheless, they have been useful in 
exploring the range o f immune responses that may occur following infection (Sayles & 
W assom, 1992). Immunity to infection has been passively transferred to naïve mice 
using hyperimmune serum or Mabs. The ability o f hyperimmune serum to alter the 
course o f parasite infection after passive immunisation depends largely on the host- 
parasite system. In the rodent malaria model P. yoelii 17XL in BALB/c mice, the 
continuous administration o f immune serum from mice that had had a single infection, or
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a single dose o f hyperimmune serum from mice that had been multiply infected and 
challenged, prevented the development o f a patent blood stage infection (Freeman & 
Parish, 1981). Jayawardena and colleagues (1978) demonstrated that the passive transfer 
o f  hyperimmune serum to CBA mice completely protected them against challenge with 
P. yoelii 17XNL. White and colleagues (1991) also studied passive immunisation with 
hyperimmune serum generated against P. yoelii  and with purified IgG fractions. Transfer 
o f  these antibodies to BALB/c mice or to out-bred ICR mice prior to challenge with 
virulent P. yoelii  17XL, and to CBA/CaJ mice prior to challenge with the avirulent 
17XNL, indicated that only the mice that had received IgG2a antibodies had an altered 
course o f infection. On the basis o f these studies. White et al. (1991) proposed that 
antimalarial antibodies o f the IgG2a subclass play a dominant role in modulating P. yoelii 
parasitaemia. In addition, previous studies showed that passive immunisation with Mab 
302 (an IgG3) directed against P. yoelii  MSP-1 conferred protection against challenge 
infection (Majarian et al. 1984). P. yoelii in laboratory mice is a murine malarial parasite 
model in which resolution of the infection depends on antibodies.
I have prepared twelve Mabs to M SP-1, an antigen o f the intraerythrocytic stage and 
merozoite surface o f P. yoelii. Five o f the antibodies were found to partially or totally 
block the invasion o f P. yoelii YM merozoites into erythrocytes, as measured by in vivo 
assays.
4.2 Inoculation of Mabs and challenge infection with P. yoelii YM
In the current study, I sought to detennine whether or not passive immunisation o f naïve 
mice with a panel o f Mabs would protect against a challenge infection with the YM  line
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o f  p. yoelii. Female BALB/c mice, eight weeks o f age, and bred under specific 
pathogen-free conditions were used. Tlie parasite stock was stored at -70°C and 
passaged once before use in each experiment. Tlie challenge was administered by 
intravenous (i.v.) injection into the lateral vein o f the tail o f 5x10^ parasitised red blood 
cells (PRBC) per mouse. Initially 2 Mabs, BIO and G3 were assessed and Mab 25.37  
(an IgG l isotype. Freeman et ah, 1980) was used as a positive control; (data not shown). 
PBS was used as a negative control because the Mabs were dissolved in this buffer. 
Mabs (1ml o f solution at a concentration o f 0.5 mg/ml) were administered by 
intraperitoneal (i.p.) injection. Tliey were administered on three occasions; one day 
before, one day after and on the day o f the challenge infection, therefore the total 
amount o f antibody was 1.5 mg/mouse. The course o f parasitaemia was monitored daily 
on blood films stained with Giemsa’s reagent. Three mice per group were used in the 
preliminary experiments to assess the protective capacity o f the antibodies. Finally ten 
mice per group were used in experiments to confirm the initial results.
Tlie Mab P2-F5 precipitated after purification by protein G. To determine whether or not 
this precipitation affected the capacity of the antibody to protect mice against a challenge 
infection, groups o f mice were immunised with three different preparations. The first 
group o f mice was immunised with a solution o f the Mab at a concentration o f 0.5  
mg/ml. The second group was immunised with the precipitated and aggregated Mab 
suspended in PBS at an estimated concentration o f 0.5 mg/ml. The third group o f mice 
was inoculated with aggregated Mab suspended in a 0.5 mg/ml solution o f the Mab. 
This last group o f animals therefore received twice the amount o f antibody compared to 
the Other two groups.
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4.3 Titre of Mabs in vivo, measured by IFA
The antibody titres in each group o f mice in the passive immunisation experiments are 
shown in Table 4.1. The antibody titres were determined by IF A for those mice which 
had received either an intraperitoneal injection o f Mabs or PBS alone as a control. Serum 
samples were taken from the tail vein at different times during the experiment: at the 
time o f the initial injection, two days after the challenge with parasites, and then one and 
tw o weeks after challenge. Tlie titre o f the antibody in the serum samples was 
detennined by fluorescence against P. yoelii  YM, using multi-well slides with a 
methanol-fixed infected erythrocyte antigen preparation, as described in Materials and 
Methods (Chapter 2). Serial two-fold dilutions o f serum were added to the wells in 
duplicate, starting with a 1:50 dilution.
The level o f antibody in the peripheral circulation was measured. Serum from mice 
immunised with P2-F5, P6-B6 and P3-D3 (antibodies that subsequently were found to be 
highly protective) had a significantly higher IF A  titre than serum from mice immunised 
P4-D 10, P1-C5, P8-D1, P1-A9, and P5-D9 (Mabs that subsequently were found to be 
not protective). Tlie IF A titres o f the animals inoculated with Mabs P8-D 4, P6-B4, BIO 
and G3 were also high. However, the titres in all groups decreased after mice were 
challenged with parasite-infected red blood cells, with the exception o f the group that 
had received Mab P3-D3; in these animals the antibody titre was higher than the initial 
measurement, two days after the challenge.
Three groups o f mice received different preparations o f Mab P2-F5, either in solution, as 
a suspension or in a mix o f solution and suspension. In Table 4.1 are shown the antibody
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titres o f serum samples in groups 9 (which received the soluble P2-F5),10 (which 
received the suspension o f P2-F5) and 11 (which received the mix o f soluble and 
suspended P2-F5). The highest antibody titre was observed in group 11. The initial titre 
o f Mab P2-F5 in this group was 1: 25600 and thereafter it decreased to 1:12800 and 
remained constant at this level during the following two weeks, compared with the titres 
in groups 9 and 10, which decreased to i:600 and 1:3200, respectively. This difference 
may be due to the initial higher concentration o f Mab used in this immunisation or the 
fact that the aggregated antibody was solubilised in vivo and released gradually into the 
bloodstream . The titre o f the antibody coiTelated well with the results o f the protection 
studies (See next section).
4.4 Protection against challenge infection by passive immunisation
Passive protection studies were used to assess the panel o f Mabs that reacted with 
merozoites and schizonts by immunofluorescence. Passive protection was evaluated by 
the ability o f the Mabs to protect BALB/c mice against a challenge infection with 5x10^ 
PRBC o f P. yoelii  YM. Figures 4.1 to 4.12 show the course o f blood stage infections in 
groups o f  mice passively immunised with Mabs P4-D10, P1-C5, P8-D1, P1-A9, P8-D4, 
P5-D9, P6-B4, P3-D 3, P2-F5, P6-B6, BIO and G3 respectively. Figure 4.13 shows the 
course o f infection in the group o f mice which received PBS alone, which was used as a 
negative control. In all cases where the Mabs were not protective (P4-D 10, P1-C5, P8- 
D l, P1-A9, P8-D4, P5-D9, and P6-B4), mice developed a high parasitaemia from day 3, 
peaking at 70-90% on day 5, and died. In contrast, mice immunised with Mabs P2-F5, 
P6-B6 and P3-D3 developed a lower parasitaemia with peaks o f 16% on day 14 (Mab 
P2-F5), 0.1% on day 9 (Mab P6-B6) and 28% on day 10 (Mab P3-D3). In the mice
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immunised with P3-D3 it was noted that at the onset o f patent parasitaemia, the parasites 
were only observed in reticulocytes, an observation not made in any other group. None 
of the mice in any o f these groups died. Of particular note was the finding that Mabs P2- 
F5 and P6-B6 delayed the onset o f patent parasitaemia by up to 5 days (Figs. 4.9 & 
4.10). The other two Mabs, BIO and G3, were partially protective because mice 
immunised with these antibodies developed parasitaemias o f 50% and 70% respectively. 
In the group o f mice immunised with G3 only 40% o f them survived (3/5 died). In both 
groups o f mice the parasites were observed in tai 1-blood films until day 22, after this day 
the parasites were not seen in blood films from any animals.
In order to confirm the results o f the preliminary passive immunisation experiments, they 
were repeated with 10 mice per group. Figure 4.14 shows the mean parasitaemia after 
challenge in groups o f mice passively immunised with Mabs P2-F5, P6-B4, P6-B6, P3- 
D3, P5-D9, BIO and G3. PBS was again used as a negative control. In spite o f the fact 
that Mab P6-B4 was not protective, this was re-evaluated because it recognised a 
different fragment o f MSP-1. Three o f the Mabs (P2-F5, P6-B6 and P3-D3) were 
confirmed to be protective (100% survival). These experiments gave similar results to 
those reported by Majarian and co-workers with ascitic fluid containing Mab 302 
(Majarian et al. 1984). Two others, Mabs BIO and G3 (which are IgG2b and IgG l 
respectively), were partially protective in this passive immunisation experiment. These 
mice developed parasitaemias that were significantly higher than those o f mice 
immunised with the other protective Mabs, the peak parasitaemias were more than 50% 
on days 13-14 but by day 22 the infection had cleared. Tlie Mabs P6-B4 (an IgG l) and 
P5-D9 (an IgG2b) were not protective because all the mice developed fulminating
infection and died at around day 8, a pattern identical to the infection in mice inoculated 
with PBS alone.
Figure 4.15 shows the effects o f the different preparations o f the protective Mab P2-F5. 
The protection conferred by this Mab varied between the different preparations. The 
results suggest that the concentration o f Mab in the peripheral circulation (as measured 
by the IF A titre) affects the course o f infection. The mice immunised with the 
suspension o f precipitated Mab produced a more marked reduction in parasitaemia. The 
group o f mice immunised with the soluble antibody had a mean peak parasitaemia of 
16% on day 14, in contrast with the groups o f mice immunised with the suspended 
antibody precipitate in PBS (Mab P2-F5/P) and the suspended antibody precipitate in the 
antibody solution (P2-F5/S) with a mean parasitaemia which did not exceed 0.17% on 
day 7, or no detectable parasites, respectively.
4.5 Attempts to develop an in vitro assay to study the effect o f the M abs on 
invasion
I tried to demonstrate whether or not the panel o f MSP-1 specific Mabs that were 
protective in passive immunisation experiments, were able to inhibit merozoite invasion 
o f red blood cells in vitro. Analysis in vitro enables the effect o f the Mabs to studied in 
isolation from cellular effector mechanisms that may operate in conjunction with the 
antibodies in vivo. P. yoelii YM -infected cells were isolated from mice, fractionated by 
centrifugation through a Percoll-glucose gradient (Deharo et ah, 1994), and the fraction 
containing late trophozoites and schizonts was diluted in RPMI 1640 medium containing 
10% o f NM S. After two washes in this medium by centrifugation for 5 minutes at 250 x
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g the cells were resuspended in medium at 1 % parasitaemia and 10% haematocrit 
(Wahlin et al. 1984). The cultures were incubated for 3 hours in the presence or absence 
o f Mabs, and every 30 min samples were removed and stained with Giemsa’s reagent to 
determine the distribution of different developmental stages (Ahlborg et al. 1996).
In the presence or absence o f Mabs, no merozoite invasion in vitro was observed, as 
assessed by the formation o f new ring stages (data not shown). Despite several attempts 
to optimise the conditions to allow in vitro development, no invasion in vitro was 
detectable, and after about 3 hours the parasites began to degenerate in culture.
4.6 Discussion.
Previous studies have demonstrated that immunisation o f mice with hyperimmune serum 
or Mabs can modulate the course o f P. yoelii infection (Freeman et al. 1980, White et al. 
1991, Majarian et al. 1984). In the present studies a panel o f Mabs was assessed for 
their protective capacity by passive immunisation experiments in mice. The properties 
o f the antibodies are summarised in Table 4.2. Some o f these Mabs demonstrated a high 
level o f protection against a lethal parasite challenge infection with P. yoelii YM. 
Specifically five out o f the 12 Mabs tested exhibited a protective effect. Mab G3 was 
partially protective (40% o f mice survived the parasite infection). Mab BIO was 
completely protective (100% survival) although with this Mab the parasitaemia reached a 
high level (70% o f red blood cells infected) on day 14 after infection. Mabs P2-F5, P6- 
B6 and P3-D3 were all highly protective (100% survival) and the levels o f parasitaemia 
were low throughout the monitored period Tliis study demonstrated that the elimination 
o f parasites is, at least in part, mediated by antibody.
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Studies on the protection o f mice by active or passive immunisation have indicated some 
o f the IgG subclasses that may be involved. Recent experiments by Akamnori and 
colleagues (1994) demonstrated that in CBA mice which had been immunised by four 
successive inoculations o f P. herghei NK65, each followed by chemotherapy, animals 
survived a subsequent challenge infection with the parasite. The sera o f the mice which 
survived the challenge had significantly higher anti-plasmodial IgGs, including IgG l and 
IgG2a. In particular, the elevated level o f IgG2a suggested that this subclass could be 
involved in a protective humoral response against this rodent parasite. In another study. 
White et al. (1991), using hyperimmune serum generated against P. yoelii  and IgG  
fractionated into its constituent subclasses by protein A-sepharose chromatography, 
showed that only mice receiving IgG2a had an altered course o f infection. These 
experiments were conducted by passive immunisation with the antibody o f BALB/c and 
out-bred ICR mice before challenge with P. yoelii 17XL . These results suggest that 
IgG2a plays a dominant role in the modulation o f P. yoelii infection. Other protective 
Mabs have also been described. Two antibodies against a 235kDa rhoptry protein (IgG l 
and IgG2a) protected mice against challenge with the virulent P. yoelii YM  line, 
converting the parasitaemia to a reticulocyte-restricted self-limiting infection (Freeman et 
ah, 1980; Holder & Freeman, 1981); Mab 302 (IgG3) is a protective M SP-1-specific 
antibody (Majarian et al., 1984); and Mab 5C10/66 is an M SP-1-specific IgG2a which is 
protective in mice against P. chahaudi infection (Lew A. et ah, 1989).
My results presented here are consistent with these other studies. Mabs P2-F5 and P6- 
B6 are both o f the IgG3 subclass, the same as Mab 302 described by Majarian et al. 
(1984), whilst P3-D3 is an IgG2a antibody, the subclass identified by the Akanmori and
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White studies. Mabs previously described and those described in this study are directed 
against proteins on the surface o f merozoites or externalised at the time o f invasion, and 
can probably prevent the interaction between the merozoite and the target erythrocyte. 
In addition, it is possible, based on other studies, that these antibodies play a role in the 
phagocytosis o f merozoites by macrophages by opsonisation. Antibodies are involved in 
the macrophage-mediated phagocytosis o f parasite-infected erythrocytes after 
opsonisation o f the infected cell (Shear et al. 1979 and Tosta et al. 1970).
The immunoglobulin titre o f sera from mice before and after challenge infection are 
shown in Table 4.1. These results show that the titre o f protective Mabs is significantly 
higher than that o f most o f the other Mabs. In addition, a difference in the serum 
antibody half life was observed between Mab P3-D3 (group 8) and the other two  
protective Mabs P2-F5 and P6-B6 (groups 9 and 11 respectively), Mab P3-D3 had the 
highest titre 2 days after the challenge infection, suggesting that the level o f IgG2a 
antibody is perhaps enhanced by activated macrophages (White et al. 1991). Taken 
together with the observations by Taylor and colleagues (1988) who demonstrated that 
IgG3 antibodies were the first antimalarial antibody o f the IgG class detected in serum of  
several strains o f mice infected with 17XL P. yoelii, it is therefore tempting to conclude 
that the IgG2a and IgG3 subclasses are the most important in the humoral response 
against P. yoelii infection. Tlie role o f the other IgG subclasses should however be 
studied further.
Using the P. yoelii murine model, I have used Mabs to confer protection against 
challenge infection and therefore identified regions o f MSP-1 that are the target of  
protective responses. Furthennore, I have identified two Mab subclasses, IgG3 and
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IgG2a, that may correlate with protection. These observations, and studies done with the 
human malaria parasite P. falciparum  (Rzepczyk et a l  1997), suggest that a strategy for 
the production o f  a vaccine against malaria must ensure that the most appropriate 
regions o f the antigen are used together with a suitable adjuvant (ten Hagen et a l  1993) 
to generate the appropriate subclass o f antibody with protective specificity.
93
Table 4.1 IF A titres o f monoclonal antibodies in serum samples
Group Mab Subclass Initial titre Titre at 
days
2 Titre at  
week
1 Titre at 2 
weeks
1 P4-D10 IgG l 1:200 NR - -
2 P1-C5 IgG l 1:100 NR - -
3 P8-D1 IgG l 1:800 NR - -
4 P1-A9 IgG2a 1:50 NR - -
5 P8-D4 IgG2b 1:51600 1:3200 - -
6 P5-D9 IgG2b 1:50 NR - -
7 P6-B4 IgG l 1:51600 1:12800 - -
8 P3-D3 IgG2a 1:51200 1:102400 1:51200 1:12800
9 P2-F5 IgG 3 1:51200 1:6400 1:6400 1:600
10 P2-F5/P IgG3 1:1600 1:6400 1:25800 1:3200
11 P2-F2/S IgG 3 1:25600 1:12800 1:12800 1:12800
12 P6-B6 IgG3 1:6400 1:12800 1:12800 1:6400
13 BIO IgG2b 1:12800 1:6400 1:3200 1:1600
14 G3 IgG l 1:6400 1:3200 1:3200 1:800
15 PBS - NR NR - -
NR: non-reactivity; -: not tested
P2-F5/P: precipitated Mab P2-F5 suspended in PBS solution.
P2-F5/S: precipitated Mab P2-F5 suspended in a solution o f soluble P2-F5.
Mabs were inoculated intraperitoneal 1 y into groups o f mice and then their titre in serum 
samples was measured by IF A using fixed blood stage parasites. The persistence o f  the 
antibody during the course o f the experiment was assessed. Tlie antibody titre was
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measured using serial serum dilutions, each point represents the average o f the results 
for 5 to 10 mice.
Table 4.2. Summary o f the characteristics o f the Mabs.
Mab Subclass Reaction
with
MSP-1
Binding to recombinant proteins
MSP- MSP- M SP- M SP- 
lE G F l. 1EGF2 I 19 I 3 3
Passive
immunisatio
n
BIO IgG2b + + partially
protective
G3 IgG l + + partially
protective
P2-F5 IgG3 + + -  +  - protective
P6-B4 IgG l + + non-
protective
P6-B6 IgG3 + + + protective
P3-D3 IgG2a + - - - - protective
The reaction with MSP-1 was detennined by immunofluorescence. Western blotting and 
immunoprécipitation. Tlie binding to the different recombinant proteins representing 
fragments o f MSP-1 was detennined by Western blotting and ELISA.
M SP -lE G F l. = First EGF-like module o f M SP-1 1 9 .
MSP-1EGF2 = Second EGF-like module o f M SP-1 1 9 .
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Figure 4.1.
Passive immunisation with Mab P4-D10, followed by intravenous challenge with 5 x 10 
PRBC per mouse. Tliis group o f three mice each received 0.5 mg/mouse o f Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). All 
mice died.
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Figure 4.2.
Passive immunisation with Mab P1-C5, followed by intravenous challenge with 5 x 10  ^
PRBC per mouse. Tliis group o f three mice each received 0.5 mg/mouse o f Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). All 
mice died.
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Figure 4.3.
Passive immunisation with Mab P8-D1, followed by intravenous challenge with 5 x 10  ^
PRBC per mouse. This group o f three mice each received 0.5 mg/mouse o f Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). All 
mice died.
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Figure 4.4.
Passive iinmuTiisation with Mab P1-A9, followed by intravenous challenge with 5 x 10 
PRBC per mouse. Tins group of three mice each received 0.5 mg/mouse o f  Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). All 
mice died.
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Figure 4.5.
Passive iirununisation with Mab P8-D4, followed by intravenous challenge with 5 x 10  ^
PRBC per mouse. Tliis group o f three mice each received 0.5 mg/mouse o f Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). All 
mice died.
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Figure 4.6.
Passive immunisation with Mab P5-D9, followed by intravenous challenge with 5 x 10  ^
PRBC per mouse. Tliis group o f three mice each received 0.5 mg/mouse o f Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). All 
mice died.
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Figure 4.7.
Passive immunisation with Mab P6-B4, followed by intravenous challenge with 5 x 10  ^
PRBC per mouse. Tliis group o f three mice each received 0.5 mg/mouse o f  Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). All 
mice died.
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Figure 4.8.
Passive immunisation with Mab P3-D3, followed by intravenous challenge with 5 x 10  ^
PRBC per mouse. This group o f three mice each received 0.5 mg/mouse o f  Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). AH 
mice survived.
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Figure 4.9.
Passive immunisation with Mab P2-F5, followed by intravenous challenge with 5 x 10  ^
PRBC per mouse, Tliis group o f three mice each received 0.5 mg/mouse o f  Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). AU 
mice survived.
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Figure 4.10.
Passive immunisation with Mab P6-B6, followed by intravenous challenge with 5 x 10  ^
PRBC per mouse. This group o f three mice each received 0.5 mg/mouse o f Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). All 
mice survived.
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Figure 4.11.
Passive immunisation with Mab BIO, followed by intravenous challenge with 5 x 10  ^
PRBC per mouse. This group of three mice each received 0.5 mg/mouse o f  Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). Ail 
mice survived.
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Figure 4.12.
Passive immunisation with Mab G3, followed by intravenous challenge with 5 x 10  ^
PRBC per mouse. This group o f five mice each received 0.5 mg/mouse o f Mab 
intraperitoneally on days -1,0 and 1 relative to the day o f parasite challenge (day 0). 
Two out o f five m ice died.
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Figure 4.13.
Inoculation o f PBS (as a negative control), followed by intravenous challenge with 5 x 
10  ^ PRBC per mouse. Tins group o f three mice each received PBS intraperitoneally on 
days -1,0 and 1 relative to the day o f parasite challenge (day 0). All mice died.
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Figure 4.14.
The course o f P. yoelii  infection in groups o f 10 BALB/c mice injected intraperitonially 
with solutions o f Mabs P2-F5, P6-B4, P6-B6, P3-D3, P5-D9, BIO and G3 followed by 
intravenous challenge with 5 x 1 0 ^  PRBC per mouse. M ice in each group received 0.2ml 
o f a 1.5mg/ml solution o f antibody intraperitoneally on days -1,0 and 1 relative to the 
day o f parasite challenge (day 0). PBS was used as a negative control. Each point 
represents the geometric mean parasitaemia o f  mice in each group and the vertical bars 
indicate the standard error.
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Figure 4.15.
Passive immunisation with different preparations o f MabP2-F5, followed by intravenous 
challenge with 5 x 10  ^ PRBC per mouse. Group o f  three mice each received either 0.5 
mg P2-F5 in solution, 0.5mg P2-F5 as a suspension o f  precipitated protein in PBS (P2- 
F5P), or 0.5m g P2-F5 as a suspension o f precipitated protein in a solution containing 
0.5m g soluble P2-F5 (P2-F5S), intraperitoneally on days -1,0 and 1 relative to the day 
o f  parasite challenge (day 0). Each point represents the mean parasitaemia o f  mice in 
each group.
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CHAPTER 5: ANTIBODY CROSS-REACTION WITH MSP-1 IN P. YOELII 
265BY
5.1 Introduction
Previous work has demonstrated antibody cross-reactivity between proteins o f different 
malaria parasites. For example, cross-reactivity was detected using an antiserum raised 
against the 230kDa P. yoelii M SP-1. Tins antiserum contained antibodies which also 
reacted with high molecular mass proteins o f P. chahaiidi and P. falciparum, although 
individual Mabs specific for each o f the proteins did not cross-react with other two  
species (Holder et al., 1983). Wanidworanun et al.(1989) identified antigens which 
cross-reacted with antibodies against the Pc96 antigen o f P. chahaiidi in the human 
malaria parasites, P. falciparum  (155kDa) and P. vivax (220kDa), and in the monkey 
malaria parasite P. cynomolgi (200kDa). To detect cross-reactivity between Pc96 and 
the other malaria parasite antigens, erythrocytes infected with the others species were 
incubated with a specific antibody (Mab 7C6) to Pc96 and binding was detected by IF A. 
Mab 7C6 reacted specifically with P. falciparum, P. vivax and P. cynomolgi. Taylor and 
colleagues (1981) used eighteen Mabs to study species-specific, stage-specific and 
serologically cross-reactive antigens o f rodent malaria parasites. Twelve distinct 
plasmodial antigens could be distinguished by using the 18 Mabs. Moreover, 6 o f the 18 
Mabs identified species-specific antigens and 8 o f them detected cross-reactive antigens 
common to rodent, primate and avian malarias.
In the past it has been difficult to identify and isolate individual plasmodial antigens and 
evaluate their roles in the immune response. Now , the use o f recombinant DNA
1 1 1
technology makes it possible to produce large amounts o f antigenic proteins from 
different malaria parasites and study them in detail. The availability o f these proteins 
together with specific Mabs, which can also be used to identify and purify malaria 
antigens, have enhanced these studies on the role o f various parasite proteins as the 
targets of, or in the induction o f an immune response. One major blood-stage vaccine 
candidate identified in a number o f plasmodial species is MSP-1 (Holder, 1988). The C- 
tenninal fragment o f Plasmodium yoelii MSP-1 has been expressed as a recombinant 
protein in E. coli and mice immunised with this recombinant protein-1 are protected 
against challenge with the lethal P. yoelii YM  strain (Daly and Long, 1993; 1995; Ling 
et ah, 1994). However, little is known about whether or not the protection is specific for 
hom ologous parasites. Different P. yoelii lines and clones may have sequence 
differences, and the importance o f these in the protective immune response is unclear. 
For example it is possible that sequence diversity at the C-tenninus o f MSP-1 leads to 
antigenic differences and this results in the evasion o f a protective immune response 
directed against M SP-1. Bums and colleagues (1989) using the P. yoelii model system  
demonstrated that the epitope recognised by the protective Mab 302, which recognises 
the C-terminal 19kDa fragment o f M SP-1, is strain variable. Tlie protective capacity of 
302 was variant-specific, passive immunisation with this antibody afforded protection 
against infection with only three o f five P. yoelii  lines.
In Chapters 3 and 4, I have described Mabs which when transferred to naïve mice were 
able to protect them against a challenge infection with parasites o f the YM  strain. To 
extend this work, the ability o f these antibodies to cross react with MSP-1 from the 265 
BY line o f P. yoelii was investigated. Tlie 265 BY line was originally isolated by I. 
Landau, Natural History Museum, Paris France, and was provided by Dr Dominique
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Mazier. A  pattern o f self-limiting infection in mice is caused by 265BY  parasites, similar 
to that o f the non-lethal 17X strain (Lucas et al., 1993). A recombinant protein 
encompassing the two EGF-like motifs o f P. yoelii 265 BY M SP-1, has been 
expressed. Tliis protein was recognised by some o f the Mabs despite a number o f amino 
acid sequence differences between the proteins from the YM  and 265BY  lines. Some of 
the Mabs also showed cross reactivity between these two lines o f P. yoelii when studied 
by IFA.
5.2. Amino acid sequence differences in the C-terminal region of MSP-1 derived 
from the YM and 265BY lines of P. yoelii
The deduced amino acid sequence o f the C-terminal 19 kDa fragment o f MSP-1 from P. 
yoelii YM  and the differences present in the protein from the 265BY  line, are shown in 
Figure 5.1. This region o f MSP-1 is conserved between the lines, but a number of 
differences can be observed. A number o f substitutions o f amino acids are evident and 
are represented by different colours. In the first domain, the amino acids substituted are 
Aspartic acid (D) by Tyrosine (Y), Threonine (T) by Asparagine (N), Tyrosine by 
Phenylalanine (F), Glycine (G) was deleted (indicated in a blue colour on Fig. 5.1), 
Glycine by Asparagine and Asparagine by Aspartic acid. In the second domain the amino 
acids substituted are Threonine by Serine (S), Isoleucine (I) by Threonine, Proline (P) by 
Tlireonine, Threonine by Alanine (A), Asparagine by Glycine, Alanine by Aspartic acid. 
Glutamic acid by Arginine (R), Tlireonine by Glycine and Isoleucine by Valine (V). In 
addition, there is an insertion o f a Threonine between Asparagine and Glutamine at 
residue 69. Overall there is an 11% sequence difference between the two forms o f the 
19kDa fragment o f M SP-1. Although some o f these substitutions are conservative, such
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as replacement o f Tyr by Phe or Ser by Tlir, the majority are non-conservative and result 
in major changes in the size and/or charge o f the individual side chains.
5.3. Assessment of antibody cross-reactivity by W estern blotting
Given the potent biological activity o f Mabs P2-F5, P 6 -B 6 , P3-D3, BIO and G3 on 
passive immunisation against the YM  line, I have examined the possible variability o f  the 
epitopes recognised by these Mabs between two lines o f P. yoelii. The cross-reactivity of 
the panel o f Mabs was tested by western blotting and ELISA. Western blot analysis was 
perfonned essentially as described in Chapter 2. Tlie combined EGF-like motifs o f YM  
and o f 265BY  MSP-1 were expressed in E. coli as recombinant proteins (G ST -M SPI 19 
and G ST-M SP 1 i9 (2 6 5 by), respectively), and purified using the method o f glutathione- 
affinity chromatography. Equal amounts o f the proteins were solubilised with sample 
loading buffer, either containing dithiothreitol (reducing conditions) or not (non-reducing 
conditions), and then subjected to electrophoresis on 15% polyacrylamide gels in 
presence o f SDS. Tlie resolved polypeptides were then transferred electrophoretically to 
nitrocellulose paper and probed with the Mabs.
The reaction o f Mabs BIO, P5-D9, P2-F5, P 6 -B 6  and P3-D3 with the recombinant 
proteins prepared under reducing and non-reducing conditions is shown in Figures 5.2,
5.3, 5.4, 5.5 and 5.6, respectively. Mab BIO recognised the combined EGF-like motifs of 
the YM  MSP-1 in both reducing (Panel A, track 3) and non-reducing conditions (Panel 
B, track 3),although the reaction with the non-reduced protein was much stronger, but it 
did not recognise the 265BY  protein (Figure 5.2, tracks 4). Mab P5-D9 recognised 
faintly both the first and combined motifs o f the YM  protein (Figure 5.3). It also
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recognised faintly the combined motifs o f the 265 BY protein. In both cases it only 
recognised the proteins prepared in non-reducing conditions (Panel B). Mabs P2-F5 and 
P6 -B 6  (Figures 5.4 and 5.5) recognised both the first and the combined motif 
recombinant proteins o f YM  M SP-1. Both Mabs also recognised the combined EGF- 
hke motifs that form the recombinant protein from 265 BY M SP-1. Mab P 6 -B 6  did not 
recognise the 265BY  recombinant protein if this had been reduced with dithiothreitol 
(Fig 5.5, Panel A, track 4), and detection o f the unreduced protein was less sensitive 
than for the YM  protein. Probably the substitution o f one or more amino acids in the 
sequence o f the protein modifies the epitope recognised by this Mab or does not allow  
the protein to refold properly after it has been subjected to SDS-PAG E under reducing 
conditions. Figure 5.6 shows that none o f the recombinant proteins were recognised by 
the Mab P3-D3. This was not surprising since this Mab only recognises a larger structure 
consisting o f the 42 kDa fragment from the YM  MSP-1 (see Chapter 3). Finally, the 
Mab G3 that recognised the combined motifs o f YM  MSP 1 19 did not recognise the 265 
BY recombinant protein in Western blotting experiments (data not shown).
5.4. A ssessm ent o f antibody cross reactivity by EL ISA
Table 5.1 shows the results o f the reaction of the different Mabs with the recombinant 
proteins when assessed by ELISA. Four o f the six Mabs cross-reacted with the 265BY  
protein.
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5.5. Discussion
The current studies using recombinant proteins derived from MSP-1 from two lines o f  
P. yoelii demonstrated that epitopes recognised by a panel o f Mabs are variable. 
However, some cross-reaction between the YM  and 265BY  MSP-1 recombinant 
proteins was observed despite the 11% sequence difference between these tw o  
polypeptides. Some o f the Mabs recognised the recombinant protein from both P. 
yoelii lines by both Western blotting and ELISA. Tins analysis o f the specificity of 
immune responses by cross-reactivity constitutes a simple approach toward the 
identification o f important conserved antigens. Table 5.2 shows a summary o f the 
characteristics o f the Mabs and their cross-reaction between the two MSP-1 
recombinant proteins. The demonstration o f disulphide-bridge dependent antibody 
binding in the Western transfer analysis suggests that the cross-reacting determinants are 
epitopes formed by amino acids sequences which are constrained in a three dimensional 
structure dependent on the cysteine residues. The reaction o f  the antibodies with the 
proteins that had not been previously reduced was always stronger than with the 
corresponding reduced samples; and there was often reaction with higher molecular mass 
material that may correspond to inter-chain disulphide-bonded aggregates o f tw o or 
more molecules. It is possible that reduction o f the samples prior to electrophoresis 
disrupts these intennolecular bonds, allowing the protein to migrate as the monomer, 
followed by at least partial refolding on the nitrocellulose. In other experiments the 
ability o f the Mabs to react with parasitised red blood cells o f P. falciparum  (Wellcome 
line) was investigated (data not shown). The Mabs did not recognise the P. falciparum  
parasites in an IFA test, suggesting that the epitopes are not fonned by sequence
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conserved between these two species. Tlie antigens o f malaria parasites are generally 
species specific, although antibodies raised against one Plasmodium  species can react 
with antigens from other species (Holder et al., 1983 and Taylor et ah, 1981), due to the 
presence o f hom ologous molecules with inter-species conserved epitopes (Ray et al., 
1994).
Ray and colleagues identified inter-species conserved antigens o f P. falciparum  that 
appeared to be the target o f protective antibodies. They detected antigens in a P. 
falciparum  lysate or in whole parasitised cells by using antibodies produced during 
repeated P. yoelii  infection of BALB/c mice. Inhibition o f P. falciparum  growth in vitro 
was observed with this mouse anti-P. yoelii serum (Ray et al., 1994), but the exact 
targets o f these protective antibodies are unknown.
O f the six Mabs used in this study, only four o f them showed some cross-reactivity with 
the 265 BY  M SP-1. Mab P3-D3 does not recognise the recombinant proteins from either 
line, because this Mab recognises a 42 kDa fragment o f MSP-1 in extracts o f parasites 
from the YM  hne which extends beyond the sequence contained within the recombinant 
protein. It will be necessary to test whether or not this Mab recognises a common 
detenninant on MSP-1 expressed in erythrocytes parasitised with P. yoelii 265 BY, for 
example by IFA or immunoprécipitation . Unfortunately, I did not have available 
parasites from P. yoelii 265 BY to assess the cross-reactivity. For the same reason, I 
could not assess the ability o f the Mabs to protect against challenge with the 265BY  line 
by passive immunisation.
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The fact that the C-tenninal region o f MSP-1 o f two different strains o f  P. yoelii  are 
substantially different, contrasts with the observation o f very high sequence conservation 
in this region o f the P. falciparum  M SP-1. It has been assumed that this protein serves a 
function essential to biology o f parasite. It is not known whether or not the observed 
sequence diversity in P. yoelii represents a selection o f variants by a protective immune 
response or variation due to some other cause. In a recent study Renia and colleagues 
(1997) investigated the ability o f a recombinant MSP-1 based on the YM  sequence to 
protect against challenge with either YM  or 265BY  parasites. The protection observed 
appeared to be largely specific for the hom ologous challenge, suggesting that the 
sequence differences do have a profound effect on the protective immunity that is 
induced. Taking into consideration the molecular parallels between the MSP-1 o f P. 
yoelii, P. falciparum,  and other malaria parasite species, this infonnation may contribute 
to the development o f an anti-malaria vaccine and an understanding o f the way in which 
protective antibody works. To obtain a full understanding, determination o f  the three 
dimensional structure o f the C-tenninal fragment o f M SP-1, together with the structure 
o f the antigen-anti body complex, will be necessary. An analysis o f the structure o f the 
antigen-antibody complex, for example by X-ray crystallography, will enable the 
identification o f  the binding sites for the protective antibodies. Additional studies using 
either natural sequence variants or mutants in which individual amino acids are changed, 
will also help define the critical amino acid sequences necessary for antibody binding. 
Some o f  the sequence differences between MSP-1 from the two lines may result in a 
reduced affinity o f interaction between the antibody and the antigen, without necessarily 
completely abolishing reactivity. The importance o f antibody affinity and avidity for 
protection on passive immunisation needs to be investigated further.
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Mabs can also be used for taxonomic studies o f malaria parasites. Despite the 
evolutionary adaptation o f parasites to various hosts, some antigens have been 
conserved. The serological cross-reaction o f antibodies to the rodent malaria parasites 
with other species, such as those that infect primates, and between parasites o f  humans 
and primates has allowed the partial identification o f antigens which may have 
significance for taxonomic studies (Taylor et ah, 1981). However, monoclonal 
antibodies for this type o f  analysis should be used with caution, because o f  the potential 
o f variation in binding, even to parasites within the same species.
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Table 5.1.
The cross reaction of Mabs with recombinant proteins based on MSP-1 from the YM  
and 265 BY lines o f P. yoelii. The antigens used consisted o f GST fusion proteins 
containing the first EGF-Iike motif from YM  M SP-1 (MSP 1EG F1 -YM ), the second 
EGF-like motif from the YM  MSP-1 (M SP1EGF2-YM ), the combined motifs from the 
YM  MSP-1 (MSP1i9(ym) ) and the combined motifs from the 265BY  MSP-1
( M S P 1 i9(265BY))-
Mab M SPIEGFI-YM  MSPJEGF2-YM M SPIjç(ym) M SPl j9^ 265by)
P2-F5 + - + +
P6-B6 + - + +
BIO - - + +
P5-D9 + - + +
G3 - - + -
P3-D3 - - - -
+: Mab recognises the recombinant protein.
-: Mab does not recognise the recombinant protein.
1 2 0
Table 5.2.
A summary o f the characteristics o f the Mabs and their cross-reaction with recombinant 
proteins based on MSP-1 from the YM and 265BY lines o f  P. yoelii.
Mab Subclass Reaction
YM
with Reaction with 265BY Passive ininiunity to 
YM challetige
P2-F5 IgG3 + + protective
P 6 -B 6 IgG3 + + protective
BIO IgG2b + - partially protective
P5-D9 IgG2b + + not protective
P3-D3 IgG2a + 7 protective
+: Mab recognises the recombinant protein or the native MSP-1 in parasite extracts.
-: Mab does not recognise the recombinant protein, but reactivity with the native MSP-1 
has not been tested.
?: Mab does not recognise the recombinant M SP-1 1 9 , but it is not known whether or not 
the Mab can recognise other fragments o f the protein.
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Figure 5. 1.
The deduced amino acid sequence o f the C-tenuinal 19 kDa fragment o f MSP-1 from P. 
yoelii YM  , showing in red (substitution) and blue (deletion) the residues that differ in 
the protein from the 265BY  line. The polypeptide consists o f two EGF-like motifs. 
Disulphide bonds maintain the confonnation and this three dimensional structure may be 
an important target for protective immunity. The substitutions in the amino acid 
sequence found in the corresponding part o f P. yoelii 265 BY MSP-1 are indicated in 
yellow (substitution) and green (insertion). There is 11% sequence difference between 
the two forms.
1 2 2
P la s m o d iu m  Y oelii
1st domain
2nd domain
Spencer 2 7/6/95 JS
Figure 5.2.
Mab BIO recognises the recombinant protein containing both EGF-like motifs o f MSP-1 
from the YM  but not the 265BY  line. Purified GST-fusion proteins were separated by 
SDS-PAG E on a 15% polyacrylamide gel, transferred to nitrocellulose and then the 
blots were probed with a 1:100 dilution o f Mab solution.
In Panel A the proteins were reduced with dithiothreitol prior to electrophoresis and in 
panel B were prepared under non-reducing conditions. The antigens were GST- 
M SPIEG FI, fusion protein containing the first EGF-like motif o f P. yoelii YM  (track 
1); GST-M SP1EGF2, fusion protein containing the second motif (track 2); GST- 
MSP1i9, fusion protein containing both EGF-like motifs o f  MSP-1 from P. yoelii YM  
(track 3); and GST-MSP1iq(265by), fusion protein containing both EGF-like motifs of  
MSP-1 from P. yoelii  265BY  (track 4). The mobility o f standard molecular mass 
markers is indicated.
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Figure 5.3.
Mab P5-D9 recognises recombinant proteins containing the first and the combined EGF- 
like motifs from YM , as well as the recombinant protein containing the combined EGF- 
like motifs o f  MSP-1 from 256BY  in non-reducing conditions. After reduction o f the 
recombinant proteins they were no longer recognised by the antibody.
Panel A corresponds to proteins prepared under reducing conditions and Panel B 
proteins prepared under non-reducing conditions. The samples and other conditions are 
the same as in Figure 5.2.
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Figure 5.4.
Mab P2-F5 recognises recombinant proteins containing the first and the combined EGF- 
like motifs from YM  M SP-1, as well as the recombinant protein containing the combined 
EGF-like motifs o f  MSP-1 from 265BY , in samples that had been treated with both 
reducing and non-reducing conditions.
Panel A  corresponds to proteins prepared under reducing conditions and Panel B 
proteins prepared under non-reducing conditions. Tlie samples and other conditions are 
the same as in Figure 5.2.
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Figure 5.5.
Mab P6-B6 recognises the recombinant protein containing the first and the combined 
EGF-like motifs o f  MSP-1 from P. yoelii YM , and also the recombinant protein 
containing the combined EGF-like motifs o f MSP-1 from 265BY  in samples that had not 
been subjected to reducing conditions. Under reducing conditions the reaction with the 
265BY  protein was abolished.
Panel A  corresponds to proteins prepared under reducing conditions and Panel B 
proteins prepared under non-reducing conditions. The samples and other conditions are 
the same as in Figure 5.2.
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Figure 5.6.
Mab P3-D3 does not recognise the recombinant proteins based on MSP-1 from either 
YM  or 265 BY treated with either reducing or non-reducing conditions. The samples 
and other conditions are the same as in Figure 5.2.
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CHAPTER 6 : GENERAL DISCUSSION AND FUTURE WORK
6 .1  General Discussion
Plasmodium yoelii  in laboratory mice represents a model in which antibodies are 
required for resolution o f infection (Weidanz & Long, 1988, Daly & Long, 1993, Daly & 
Long, 1995; Ling et ah, 1994). Mab 302 raised against M SP-1, provided protection 
against challenge infection with this species o f Plasmodium  (Majarian et ah, 1984). In 
this work, I have produce monoclonal antibodies specific for M SP-1. Initially, I used a 
recombinant protein (G ST -M SPI 1 9 ) to immunise the mice, because immunisation with 
recombinant P. yoelii  GST-MSPIiq could elicit a protective host antibody response 
(Daly & Long, 1993 & Ling et ah, 1994).
The protective and partially protective Mabs (P2-F5, P 6 -B 6 , P3-D3, BIO and G3) 
obtained in this work, which provided passive protection against challenge infection with 
P. yoelii, give good evidence that antibodies play a very important role in the immune 
response to this parasite. Mabs BIO, G3, P2-F5 and P6 -B 6  recognised epitopes localised 
to the C-tenninal 19 kDa fragment o f M SP-1, while P3-D3 recognised a 42 kDa 
fragment o f the MSP-1 molecule, that includes M SP-1 1 9 . These results, together with the 
fact that this protein is homologous to the P. falciparum  M SP-1, show that the C- 
tenninus o f MSP-1 is an important candidate for a blood-stage malaria vaccine. This is 
consistent with an important role for M SP-1 ,9, which remains bound to the surface o f the 
merozoite, and the demonstration that the antibodies to this region o f the molecule can 
inhibit P. falciparum  invasion in vitro (Chappel & Holder 1993). Mab 302 is a protective 
IgG3 antibody, which recognises the first EGF-like motif and the native P. yoelii  MSP-
1 2 8
I i 9 . Calvo and colleagues (1996) hypothesised that the first EGF-like m otif could elicit 
protective responses since Mab 302, which was mapped to this region, could passively 
protect mice against a lethal infection o f P. yoelii. However, only the mice immunised 
with a recombinant protein containing both EGF-like motifs produced antibodies which 
could recognise the native M SP-1, and were protected against challenge infection with 
P. yoelii  (Ling et ah, 1995). Two o f the protective Mabs (P2-F5 and P 6 -B 6 ) obtained in 
this work are o f the IgG3 subclass and both recognised the first and combined EGF-like 
motifs o f M SP-1 1 9 . The other protective Mab (P3-D3) is an IgG2a and it recognised a 42 
kDa fragment o f MSP-1 when an extract o f schizonts and trophozoites was used as 
antigen in Western blotting. It does not recognise the M SP-1 , 9  and M SP-1 3 3  
recombinant proteins, suggesting that the 42kDa fragment needs to be intact for binding 
to take place. A striking observation was that all protective Mabs were o f  the IgG3 and 
IgG2a subclasses, but not all Mabs are specific for the first EGF-like motif. In fact, only 
P2-F5 and P6 -B 6  bind the first motif alone. Tlie partially protective Mabs are o f  the 
IgG2b and IgG l subclasses and they recognised only the combined EGF-like motifs of 
M SP-1, suggesting that the protection in passive immunisation may depend on the 
immunoglobulin subclass. The results o f this study show that antibody-mediated 
mechanisms are important for immunity to P. yoelii. Antibodies appear to be required in 
order for most mice to resolve their infections, but it is not clear if the protective 
antibodies must be o f  a certain subclass (Sayles & Wassom, 1992).
In the P. yoelii model, the P. yoelii 17X parasites are reticulocyte restricted through the 
course o f an infection. In the passive immunisation experiments using Mab P3-D3 only a 
few infected cells were visible and these were reticulocytes. Tlie significance o f this
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observation is not known, but it will be of interest to confirm whether or not there is a 
correlation between response to the 42kDa fragment and reticulocyte restriction.
Miller and colleagues (1997) comment that the essential criteria for a successful vaccine 
are: (1) target epitopes that have limited or no polymorphism; (2 ) human-compatible 
adjuvant; and (3) a strategy to successfully identify such an antigen /adjuvant formulation 
for manufacture and further development. The work described here helps to define the 
importance of MSP-1 for vaccine development. Mabs can also be used to purify malaria 
antigens, even if the particular Mab is non-protective or non-inhibitory because the 
antibodies to other epitopes may block the invasion (Miller et ah, 1986). Mab P6-B4, 
that was not protective against a challenge infection of P. yoelii YM bound to a 
recombinant protein based on the 33 kDa fragment, and this is the first time that such a 
specificity has been reported.. This monoclonal antibody may be of use to study 
proteolytic processing of the P. yoelii MSP-1.
In the P. yoelii model, the secondary structure of MSP-1 is important for both 
antigenicity and induction of a protective response; reduced and alkylated recombinant 
proteins (GST-MSPI1 9 , GST-MSP1 EGF 1 and GST-MSP1EGF2) were not recognised 
by Mabs on Western blots. Several epitopes common to two different lines of P. yoelii 
have been defined by various Mabs raised against the YM protein. These Mabs have also 
been used in other collaborative work to study the expression and antigenicity of the C- 
terminal domain of the P. yoelii MSP-1 in Salmonella typhimurium (Somner et ah, 
1997, submitted for publication).
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In previous studies with P. falciparum it was found that some Mabs directed to the C- 
terminus of MSP-1 could inhibit the cleavage of the 42 kDa fragment of MSP-1, and 
that these Mabs were those that inhibited invasion in vitro. Therefore it appears that one 
of the mechanisms by which antibodies to MSP-1 can inhibit invasion is by preventing 
secondary processing. It will also be of interest to determine whether or not the 
protective Mabs defined in this study have similar effects on the processing of the P. 
yoelii MSP-1. The definition of the protease involved in the processing and its 
specificity may also lead to design of drugs which inhibit this process.
62  Future work
A future experiment will be to determine the cross-reaction of the Mabs with other 
species of rodent malaria, to demonstrate specificity for P. yoelii. If any of the antibodies 
react with other malaria parasite species or lines it will be of interest to evaluate the 
antibodies ili passive itnlnunlsatioli cxpcriiiieiiLs. Analysis o f  the am ino acid sequence of 
the MSP-1 from the other parasites may provide clues to the residues that contribute to 
the epitopes. It will be of interest to evaluate Mab P3-D3 by passive immunisation 
against non-lethal P. yoelii 17 X, which preferentially infects reticulocytes, in particular 
because in mice immunised with this Mab any parasites detected in the first days after 
infection with the YM line were present in reticulocytes. Also, it is necessary to assess 
the protective Mabs in passive immunisation against the 265BY line, in light of the 
results obtained by Western blotting and ELISA. It is expected that Mabs P2-F5 and P6 - 
B6  win protect naive mice against challenge infection with P. yoelii 265BY, because 
these Mabs appear to cross-react with this strain.
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Passive immunisation with a combination of two Mabs may confer more effective 
protection than that provided by a single Mab alone. Li particular the combination of 
Mabs which are clearly against different epitopes, for example BIO or G3 with P6 -B6  or 
P2-F5, and the combination of Mabs that interacted in the competitive ELISA, would be 
of interest. If it is true that the steiic inhibition of Mabs P6 -B6  with P2-F5, and G3 with 
BIO happens in the way suggested by the competition ELISA, then, one would expect to 
see no additive effect when the Mabs are evaluated together by passive immunisation.
It will be important to map the epitopes recognised by the Mabs on the MSP-1 protein, 
using mutagenesis of selected amino acids and possibly identifying functional domains of 
the protein (Farley & Long, 1995). These studies will help to define in fine detail regions 
of the protein that are important in eliciting a protective response and consequently in 
the development of a vaccine. The three dimensional structure of MSP-119 and of the 
antigen-antibody complex would provide precise structural information, that could be 
obtained by X-ray crystallography.
Li order to evaluate the importance of the antibody subclass in the protection conferred 
with the Mabs, passive immunisation of SCID (severe combined immune deficiency) 
mice and challenge with P. yoelii YM, would be very informative. These mice do not 
generate functional T or B cells because they have a defect in V-(D)-J recombination 
(Bosma and Carroll, 1991). SCID mice will allow an assessment of the Mabs without 
any interference from a B or T cell response. A comparison of the percentage 
patasitaelnla and tlie percentage survival in the SCID mice compared with control 
normal BALB/c mice immunised in the same way would indicate whether or not 
additional factors, rather than just antibody blocking of invasion, are important
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Itnmunoglobulin G (IgG), can undergo partial proteolytic cleavage by papain in the hinge 
region, to produce two identical fragments that can bind antigen - Fab (Fragment 
antigen binding) and a fragment which can not bind antigen - Fe (Fragment 
crystaUisable). Using these fragments it would be possible to determine which part of 
the protective monoclonal antibody is responsible of the protection, and whether or not 
the intact molecule is required. For example, three groups of mice could be passively 
immunised with Fab fragment, F(ab')2  fragment and the complete IgG molecule. This 
experiment would allow the determination of which part of the Ig is responsible for the 
protection, and whether or not the whole molecule is required.
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